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sununarv. 
An investigation was carried out to examine the production of the 
inflammatory cytoldnes ILla, IL1ß, IL6, TNFa, and TNFß in two tumour cell lines, 
the MCF-7 breast cell line and the T-24 bladder cell line, and in samples of breast, 
bladder, lung and ovarian tumours. 
Two methods were used to investigate cytokine production. These were the 
polymerase chain reaction method (PCR) to examine cytokine mRNA production and 
immuno-staining of frozen or paraffin-embedded tissue sections to demonstrate the 
presence of the cytokine polypeptide directly. In the PCR experiments, the most 
frequently found cytokine was IL6, followed by ILla. Only a few tumours of any type 
displayed TNFa, and even fewer produced TNFß. In the immunostaining experiments 
performed on frozen sections, ILla and IL6 proteins were detected in sections of tumours 
which gave positive results with PCR. Cell phenotyping indicated that the II. l a and IL6 
were probably being synthesised by the tumour cells themselves although there was 
lymphocyte infiltration in every section examined. In the immuno-histology study 
performed on the paraffin-embedded sections, a new collection of tumours was used. 
These tumours were not subjected to parallel PCR due to size of tumour samples being 
too small. The results obtained from these experiments conflicted with the results 
observed in the PCR study. ILIA was detected in all of the breast tumours used for 
immuno-histology but in none of the breast tumours in the PCR experiments. 
This conflict was probably due to a lack of sensitivity in the method used to detect PCR 
products. 
14 
While the conflict could not definately be resolved, it was thought that the results of the 
immuno-histology experiments were more accurate as they detected expression of 
cytokine protein on a cellular scale. The immuno-histology experiments demonstrated that 
some tumour cells produced ELI (x in breast and bladder carcinomas, and some produced 
IL6 in breast and lung carcinomas. 
Overall, the results of the experiments descibed in this thesis demonstrated that all 
of the tumour types examined could produce inflammatory cytokines, and that two of 
these, ILI a and IL6 could be detected in with some frequency in tumour samples of all 
types. From the results presented in the thesis, and examination of the literature, IL6 
would be a good candidate for development as a new biochemical tumour marker but 
limitations on the accurate measurement of lLla in serum means it is not suitable as a 
biocheical marker. Expression of the inflammatory cytokines in breast tumours would be 
particularily worthy of future investigation, given the nature of the reported experimental 
resultsa and the absence of much evidence for cytokine production by this tumour type. 
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Chapter 1: Introduction. 
1.1: General. 
Cancer is one of the world's most serious medical problems. In the west, it 
is second only to heart disease in terms of adult mortality rates, and in childhood 
second only to accidental death. Indeed it has been forecast that it will become the 
major cause of death as medical advances in the treatment and management of other 
conditions continue. (Souhami and Tobias, 1986) 
Unlike many other diseases, cancer is a broad term for a number of different 
disease states which have a variety of symptoms and causes. However, it seems 
possible that these disease states are caused by a similar basic mechanism. An 
infectious disease such as influenza has one specific cause - the influenza virus - and 
one set of symptoms arising from infection of a specific part of the body by the 
virus. By contrast, cancer displays no uniform set of symptoms and can arise in 
almost any type of tissue. At a gross level, it is a descriptive term for a group of 
conditions which if left untreated may result in the death of the afflicted individual 
due to overgrowth and spread of the cancer cells. At the cellular level it is a disease 
of abnormal cell proliferation and growth. The normal controls for regulation of 
cell growth and mortality are absent and the cancer cells keep dividing indefinitely 
(Devita et al, 1989). 
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Normal checks which prevent the overgrowth of one tissue by another are defective, 
as is the mechanism whereby cells of a particular type are fixed to a particular 
location. Cancer cells can migrate from their parent tissues to other parts of the 
body and grow there (this is called the formation of metastases). It is the burden 
induced on the body by tumour growth and the impairment of organ function by 
growth of invasive metastases which leads to death (Rubin, 1978). 
Tumours can be either benign (simple is another term), or malignant. Benign 
tumours are localised, often surrounded by a capsule and rarely give rise to serious 
effects. When they do, this is usually due to their mass causing pressure on vital 
organs or by their secretion of abnormal amounts of biochemical products. 
Malignant tumours are not localised although they do invade locally into 
surrounding tissues. They also form metastases in distant parts of the body, in which 
they then become invasive. They frequently cause death by extensive damage to the 
normal tissue they invade and by the metabolic effects of general tumour burden. 
While tumours may be generally divided into the two types above, this 
classification is by no means absolute; indeed it is an operational one convenient for 
the pathologist or clinician. 
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Benign tumours may progress to become malignant. The common wart for example, 
which is a papilloma of the skin, never becomes malignant but papillomas of the 
bladder or colon do so with high frequency. (Calmar and Paul, 1978) 
One of the most important features of a tumour is that as it progresses to 
malignancy its cells transform. Tissue specific antigens are progressively lost and 
tissue specific functions disappear. This is associated with changes in the 
chromosomes of the tumour cells. Malignant cells are found to have very different 
morphology and biochemical properties from normal cells of their tissue of origin. 
This is very important in their pathological classification. Pathologists categorise 
tumours by their state (benign or malignant), by their embryonic tissue of origin and 
by their cell morphology (Moore, 1975). The table overleaf shows the most common 
types and how they are defined: 
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Table 1.1: Categorisation of Tumours (from Calman and Paul, 1978) 
Tissue Type: Normal Cell Name for Benign Name for 
Type: Tumour: Malignant 
Tumour: 
Connective Fibrocyte Fibroma Fibrosarcoma 
Tissue: Fat cell Lipoma Liposarcoma 
Osteocyte Osteoma Osteosarcoma 
Muscle Myoma Myosarcoma 
Vascular Endothelial cell Haemangioma Haemangio- 
Endothelium: sarcoma 
Epithelium: Squamous and Papilloma Carcinoma 
transitional (Squamous and 
basal cell) 
Glandular Adenoma Glandular 
Carcinoma 
Neural: Glial Glioma Neuroblastoma 
Nerve Ganglionic 
Neuroma 
Melanoblast Melanoma Malignant 
Melenoma 
Haemopoetic: Reticulum cell Lymphoma Lymphosarcoma 
Plasma cell Reticulosarcoma 
Leucocyte Myeoma or 
Leukaemia 
Embryonal: Embryonal Teratoma Terato-carcinoma 
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1.2: Importance of Biochemical Markers 
to the Diagnosis and Monitoring of Cancer. 
Many tumours are difficult to diagnose in their early stages. Often the patient 
experiences no noticeable symptoms and there is nothing which can be detected 
externally. In many cases, by the time detectable symptoms or signs do manifest 
themselves, the tumour is quite advanced and has already metastasised, making a 
successful prognosis for the patient more unlikely. This is particularly true of cancers 
such as ovarian carcinoma, in which metastatic spread is very rapid and mortality rates 
are high. It is a consequence of the difficulty of making early diagnoses of cancer that 
clinicians wish to establish new diagnostic tools which may enable early diagnosis 
even before symptoms or signs become evident. 
Following diagnosis it becomes important that clinicians can monitor the 
condition of the tumour as treatment proceeds. 
To aid in the diagnosis and treatment of cancer much work has been reported, 
the aims of which are to find and study biochemical markers that may contribute either 
to diagnosis or therapy (see for example Beastall et al, 1991). 
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These so-called tumour markers are macromolecules, the appearance of which is 
related to the genesis and growth of malignant tumours and the concentrations of 
which may correlate with the tumour burden present in individuals. Tumour markers 
are usually classified as cellular or humoral in type. 
1.3: Definitions of the Two Tumour Marker Types. 
1.3.1: Cellular tumour markers. These are antigens located on the plasma membrane 
of cells and are often glycoproteins or complex carbohydrates. They may also be 
hormone or growth factor receptors. Cellular tumour markers enable the detection of 
tumour cells by a variety of means, such as immuno-staining, or in-situ hybridisation. 
1.3.2: Humoral tumour markers. These are substances which can be detected in 
serum, urine and other body fluids at concentrations exceeding those found normally. 
They may be products synthesised and excreted by tumour tissue, shed cell surface 
receptors, substances released on tumour disintegration, or substances formed as a 
reaction of the body to the tumour. 
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IA: Criteria for an Ideal Tumour Marker (from Beastall et al, 1991). 
The criteria which an ideal tumour marker should display are: 
1) High specificity, i. e. not detectable in benign disease or in healthy individuals. 
2) High sensitivity, i. e. detectable very early when only a few cancer cells are 
present. 
3) Organ specificity. 
4) Correlation of concentration of marker with tumour stage and mass (the tumour 
burden). 
5) Correlation with prognosis. 
6) Reliable predictive value (i. e. the concentration of the marker giving a reliable 
prediction of the state or size of the tumour). 
Unfortunately there are no markers which fulfil all of these criteria. However, 
some markers are in routine clinical use, having fulfilled several of the criteria and 
examples of these are: 
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1.5: Examples of Tumour Cell Markers. 
1.5.1: Alpha fetoprotein (AFP). 
This is a 70 kilodalton (kd) relative molecular mass protein with al electrophoretic 
mobility that is synthesised by parenchymal cells of the liver, by the yolk sac, and 
by the gastrointestinal tract of the fetus. It was first characterised by Bergstrand et 
al (1956). It is the major protein in serum of the early fetus, and is present in the 
serum of adults at very low concentrations. In 1963, Ablev et al demonstrated that 
AFP was present in transplantable hepatomas of mice, and in 1964 Tatarinov 
detected AFP in the serum of human patients displaying hepatocellular carcinoma. 
Subsequent development of sensitive radio-immuno assays for AFP, including one 
by Waldman et al (1974), showed a strong association between AFP production and 
hepatocellular carcinoma. Raised concentrations of AFP in serum (greater than 
40ng/ml) were observed by Waldman et al in over 72 % of patients with this 
carcinoma. 
Since in normal individuals, AFP levels in serum occur only during pregnancy 
or in the first year of life, choice of an appropriate cut off level for AFP in the serum 
of individuals of normal physiology makes it quite a specific marker. 
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AFP exhibits a sensitivity in the range of 60- 80 % for hepatomas, and 50- 70% for 
non-seminomatous germ cell testicular carcinomas (according to Beastall et at, 1991). 
AFP is of greatest usefulness in diagnosis of hepatoma and in monitoring its 
response to therapy. 
1.5.2: CA 125. 
This is a glycoprotein with a relative molecular mass of approximately 200kd and 
is defined by its reactivity with the monoclonal antibody OC 125. It was discovered 
in 1981 (Bast et at, 1981). In a further study, (Bast et at, 1983) it was demonstrated 
that raised concentrations of CA 125 occurred in serum in 82% of patients with 
ovarian carcinomas and so CA 125 displays good sensitivity for this condition. The 
value of using CA125 to screen for ovarian cancer was further examined in a later 
study (Jacobs et at, 1988). Over 1000 apparently healthy postmenopausal women 
were examined for the presence of significant concentrations of CAI 25 and this was 
correlated with the successful diagnosis of ovarian cancer. The specificity of using 
CA125 to diagnose ovarian cancer was 97%, compared with 97.3% for diagnosis by 
vaginal examination. The main clinical application of CA 125 today is in the 
monitoring of therapy and detection of clinically occult recurrences in patients with 
ovarian cancer. According to Jacobs et at, alterations of CA 125 levels in serum 
correlated with disease response to therapy in 94% of the cases studied. Serial levels 
of CA 125 can detect clinically occult recurrences with lead times of up to 17 
months, with a median lead time of 3-4 months. 
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While these are two examples of currently used markers, there are a great 
many more, and it seems probable that the number of markers in use will grow as 
more is discovered about tumour biology. 
1.6: The Relationship Between Tumours and Cytokine Production and the 
Possibility of their Selection as New Tumour Markers. 
1.6.1: Introduction. 
An essential part of the immune response (the way in which the body 
responds to invasion by foreign organisms) is the secretion of certain chemical 
messengers by a range of different cells in the body, including lymphocytes. These 
messengers help to determine, in turn, the responses of other cells and effects like 
inflammation which commonly accompany the immune response. These chemical 
messengers are called cytokines. Many of the cytokines also have other roles out 
with the immune response (see later) and there is a considerable body of evidence 
that some cytokines are associated with, or produced by, certain types of tumour: 
in particular the cytokines Interteukin la (ILl(x), Intedeukin lß (IL1ß), Interleukin 
6 (IL. 6), Tumour Necrosis Factor a (TNFa), and Tumour Necrosis Factor ß (TNFß). 
If production of any of these cytokines could be confirmed in a particular type of 
tumour, and found to exhibit suitable sensitivity and specificity, then they might 
make useful new markers for certain types of tumour 
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The following sections of this dissertation (1.6.2 - 1.6.5) review briefly in turn 
the characteristics and effects of the four cytokines including their interaction with 
one another. This is followed (1.6.6) by a review of the evidence for an association 
between each cytokine and tumours of various types. 
1.6.2: Characteristics and Effects of Interleukin 1 (ILI). 
Interleukins I a, and Iß are separate gene products, but are recognised by the 
same receptors and are very closely related both in terms of their three dimensional 
structure and biological activities. They are often considered together as Interleukin 
1. 
1.6.2.1: Discovery of IL1. 
In 1972 Gery et al discovered a factor in the supernatants from stimulated 
human and murine leucocyte cultures which could induce mitogenic activity in 
murine thymocytes and in 1979, Togawa et al characterised a factor with similar 
biological properties and showed that it had two distinct forms with different 
molecular masses. The factor was named interleukin I (or IL1), by Aarden et al in 
1979 who derived the name to denote a chemical messenger allowing signals to pass 
between leucocytes. The two forms are distinguished as ILIa and B. 
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1.6.2.2: Size and structure of IL1. 
cDNAs for IL la and ß were cloned by Auron et al in 1984 (IL 1 ß), and 
Lomedico et al, also in 1984 (murine ILl a). Both forms are synthesised as 31 kd 
precursors which are then post-transcriptionally modified. The bio-active forms of 
IL I have a relative molecular mass of 17kd. Mature human IL 1ß has been 
crystallised and its three dimensional tertiary structure determined (Priestle et al 
1989). It is folded into 12 ß strands held together by hydrogen bonds. 
1.6.2.3: Constitutive Expression of ILl in Healthy Tissue. 
There is little evidence for constitutive expression of ILI in healthy tissue. 
Hauser et al (1986) demonstrated that IL I was present in normal human epidermis. 
Care had to be taken to ensure that the cells used in the experiment remained 
unstimulated. Unstimulated peripheral blood mononuclear cells (PBMCs) were used 
as a negative control and PBMCs stimulated with phytohaemagglutinin (PHA) were 
used as a positive control. The detection methods used were the Lymphocyte 
Stimulatory Factor (LAF) assay (the standard bio-assay for IL I at the time) and an 
indirect assay which measured IL 1-induced prostaglandin E2 production. 
Detectable IL1 was demonstrated in the unstimulated epidermis with both 
assays. No IL1 was found in the unstimulated PBMCs; IL1 activity was found in the 
stimulated PBMCs. 
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However, the results were inconclusive, as it could not be said for certain if 
the IL1 found in the epidermal tissue came from epidermal cells themselves or from 
lymphocytes also present in the tissue. The current view, as expressed by Dinarello 
(1992) is that there is no significant expression of IL1 in normal healthy 
unstimulated cells. 
(Even in lymphocytes, production is always due to stimulation. ) 
1.6.2.4: Production of ILl following Stimulation. 
Following stimulation a variety of cell types can produce IL1. These include 
monocytes, tissue macrophages, vascular endothelial cells, astrocytes, microglia, 
glioma cells, and keratinocytes (Emery and Salmon 1991). 
In the immune system, the production of ILI is mainly from stimulated macrophages. 
T-cell factors, principally IL2 and interferon gamma (IFNI'), activate macrophages 
and cause them to produce IL I. IL I production is inhibited by IL4 (in humans 
only) and prostaglandin E2 and TNFa can stimulate IL1 production (Dinarello, 
1992). 
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1.6.2.5: Method of Signal Transduction Caused by 1L1. 
The overall method of signal transduction caused by ILl in its target cells is 
unclear. Both a cyclic AMP and protein kinase pathway and a serine kinase and G 
protein pathway have been proposed (Emery and Salmon 1991). 
1.6.2.6: Effects of ILI. 
ILl can affect many kinds of cell. In the immune system Simic et al (1985) 
showed that ILI could cause the production of IL-2 in lectin-stimulated T-cells, and 
also up-regulate their IL-2 receptors. IL I can also affect B-cells by increasing B-cell 
proliferation and antibody formation. The effect is synergistic with IL6 (Dinarello 
1992). 
Bevilaqua et al (1985) showed that IL I affected the vascular endothelium by 
causing increased adhesion of PBMCs to it. They proposed that this might be how 
leucocyte-vessel wall interactions are localised at sites of inflammation. Dejana et 
al (1987) demonstrated that IL1 could affect the vascular endothelium in other ways, 
by causing (a) prostaglandin 12 (PGI2) production, (b) platelet activating factor 
production and (c) plasminogen activator inhibitor production. It thus appears to play 
a role in thrombosis, probably by augmentation at the site of damage. 
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1.6.2.7: Systemic Role of ILI. 
If IL1 is administered systemically it has a important role in the mediation of 
inflammation. Tewari et al (1990) demonstrated that following intravenous 
administration, recombinant ILIß caused symptoms of acute inflammation, including 
increased heart rate, low grade fever and rigors, in human volunteers. Platelet counts 
rose by 50%, and neutrophil-dominated leucocytes rose by 100% . 
Similar effects had previously been observed in rabbits in work by Okusawa et al 
(1988), who found that administration of recombinant IL Iß to rabbits caused 
increased heart rate, a fall in vascular resistance, a fall in arterial pressure, and a fall 
in central venous pressure. The effect was enhanced by co-administration with 
TNFa (see later), an example of cytokine synergy (for more information on the 
proinflammatory properties of IL I see Dinarello 1991). 
The table overleaf summarises the properties of IL 1 (after Dinarello, 1992). 
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Table 1.2: A Summary of the Biological Properties of ILL 
(After Dinarello. 1992) 
Immunological Properties: 
a) T-cell activation: synergy with IL6 for IL2 synthesis. 
b) Increased IL2 receptor expression. 
c) B-cell activation via induction of IL6; synergy with IL4. 
d) Stimulation of Natural Killer (NK) Cell activity; synergy with IL2 and 
interferon. 
e) Lymphokine gene expression. 
Pro-inflammatory properties: 
a) Fever, anorexia, neuropeptide release. 
b) Gene expression for complement and other acute phase proteins, 
suppression of cytochrome P450 synthesis. 
c) Endothelial cell activation. 
d) Neutrophilia. 
e) Increased adhesion molecule expression. 
f) Neutrophil tissue infiltration (via IL8). 
g) Beta islet cell cytotoxicity. 
h) Raised amino acid turnover; hyperlipidaemia. 
i) Cyclooxygenase and lipoxygenase gene expression. 
j) Increased synthesis of collagenases and collagens; osteoblast activation. 
32 
163: Characteristics and Effects of Interleukin-6 (IL6). 
1.6.3.1: Discovery of 1L6. 
It was shown in the early 1980's that activated B-cells in culture required at 
least 2 different factors to stimulate antibody production (Yoshikazi et al, 1982). 
One was responsible for growth of the activated B-cells (B-cell growth factor) and 
the other for the subsequent induction of antibody production (B-cell differentiation 
factor). This second factor was first identified by Howard et al (1983) and named 
IL6 in 1988. Since 1983 it has been well characterised: 
1.6.3.2: Size and Structure of IL6. 
IL6 is a phosphoglycoprotein of (in the mature form) 184 amino acids, and 
has a relative molecular mass of 21-28kd. It shows homology with 
Granulocyte/Monocyte colony stimulating factor (GM-CSF). Other synonyms 
include: 
B-cell Stimulating Factor-2 (BCSF-2), Interferon ß2(IFN ß2), 26 kd Protein, 
Myeloma/Plasmacytoma Growth Factor, Hepatocyte Stimulatory Factor, 
Macrophage/Granulocyte Inducing Factor 2, and Cytotoxic T-cell Differentiation 
Factor (see reviews by Kishimoto, 1989; and Hirano, 1992). 
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In the immune system, IL6 is produced principally by activated macrophages 
as is IL1. IL1, IL2, TNFct and IFNF (Interfearon Gamma) are inducers of IL6 
production (Hirano, 1992) A summary of the large number of different cells 
producing IL6 is shown in the table overleaf (after Hirano, 1992). 
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Table 1.3: Cells Which Produce IL6 (after Hirano, 1992). 
Normal Cells: 
T-cells 
B-cells 
Monocytes 
Fibroblasts 
Keratinocytes 
Endothelial Cells 
Astrocytes 
Bone marrow 
Mesanglial cells 
Cell Lines: 
T-cell lines (HTLV -1 transformed) 
Monocyte lines (U937, P388D1) 
MG63 osteosarcoma line 
T24 bladder line 
A549 lung carcinoma line 
SK-MG-4 glioblastoma line 
U373 astrocyte line 
Tumour Cells: 
Cardiac Myxoma Cells 
Myeloma cells 
Hypemephroma cells 
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1.6.3.4: Effects of 116 Within the Immune System. 
In the immune system IL6 has a key role in the differentiation of B-cells. 
Hirano et al (1984) showed that cultured B-cells, which had been activated with the 
Staphylococcus aureus Cowan I mitogen, were induced to produce immunoglobulins 
IgG, IgM, and IgA when IL6 was administered to them at non-pharmacological 
concentrations. IL6 administered to unstimulated resting T-cells had no effect. 
Garman et al (1987) showed that IL6 also had an effect on T-cells, at least in 
the mouse. They showed that IL6 could induce murine T-cells to produce IL2. 
Khazarami et al, in 1989, showed that IL6 affected neutrophils and monocytes 
by priming the oxidative burst response. This is a key reaction in these cells, being 
the mechanism whereby they generate hydrogen peroxide and oxygen radicals, used 
in target cell elimination. 
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1.6.3.5: Systemic Effects Of IL6. 
IL6 also has important systemic actions, the most important of which is the 
mediation of the acute phase response to injury. This is a response to tissue injury, 
neoplastic growth, infection or inflammation. It is characterised close to the area of 
cell damage by platelet aggregation, clot formation, dilation and leakage of local 
blood vessels and accumulation of granulocytes and monocytes, which in turn release 
the acute phase cytokines. These include IL 1,116, and TNFa which cause fever, 
leucocytosis, increased erythrocyte sedimentation rate, complement activation and 
dramatic changes in the concentrations of some plasma proteins. These proteins, 
known as the acute phase proteins, include C-reactive protein (CRP) and serum 
amyloid-A, which are synthesised principally in the liver (Heinrich et al 1990). 
While both IL1 and TNFa are involved in the acute phase response, the principal 
mediator is IL6. 
Gauldie et al (1987) showed that the synthesis of the acute phase proteins by 
hepatocytes was caused by IL6. They found that anti-IL6 antibodies could block the 
stimulatory effects on hepatocytes and that in a liver cell line, recombinant IL6 could 
induce synthesis of all the major positive acute phase proteins. 
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Nijstein et al (1987) demonstrated a close correlation between the 
concentrations in serum of IL6 and CRP synthesis in patients with severe burns, and 
concluded that IL6 was the primary agent of the acute phase response in humans. 
Further evidence was provided by Castell et al (1988) who showed that recombinant 
IL6 could induce the synthesis of serum amyloid A (SAA), CRP, haptoglobin a, 
antichymotrypsin, and fibrinogen. 
Shenkin et al (1989) showed that there was a connection between IL6 
production and the injury caused during surgery. A rise in the concentration of IL6 
in serum was detected within 90 min of the initial surgical incision. The period of 
maximum IL6 concentrations correlated with the length of the operation. Shenkin 
et al concluded that IL6 might be of value in the study of the metabolic response to 
injury. The study was subsequently followed up by the same team (Cruikshank et 
al, 1990), who confirmed the increases in the concentration of IL6 in serum during 
surgery. There was also a correlation between the concentration of IL6 in serum and 
the synthesis of the acute phase protein C-reactive protein (CRP): the team 
speculated that the CRP synthesis was IL6 induced. 
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1.6.3.6: IL6 as a Stimulator or Inhibitor of Cell Growth: 
There is also some evidence for IL6 being a growth factor/inhibitor. Chen et al 
(1988) showed that IL6 at non-pharmacological concentrations could inhibit the 
growth of a leukaemia cell line and two breast cell lines. These findings are 
discussed further in this dissertation (p 197). 
Shimizu et al in 1988 showed that IL6 could also have a non-pharmacological 
growth promoting effect on a lymphoma-derived T-cell line which displayed IL6 
receptors. 
The table overleaf summarises the properties of IL6 (after Hirano, 1992). 
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Table 14: A Summary of the Biological Properties of IL6 (from Hirano, 1992). 
1) Induction of Differentiation or Gene Expression: 
IL6 Causes: 
a) B-cell differentiation. 
b) Induction of acute phase protein synthesis. 
c) Cytotoxic T-cell differentiation. 
d) Induction of IL2 production and IL2 receptor expression in T-cells. 
e) Macrophage differentiation. 
f) Neural cell differentiation. 
g) Maturation of megakaryocytes. 
h) Induction of ACTH synthesis. 
2) Stimulation of cell growth: 
IL6 Causes: 
a) Hybridoma/plasmacytoma/myeloma growth. 
b) T-cell growth. 
c) Lennert's T-cell lymphoma growth. 
d) EBV-transformed B-cell growth. 
e) Haematopoietic stem cell growth. 
f) Mesangial cell growth. 
g) Renal carcinoma cell growth. 
h) Keratinocyte growth. 
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Table 1.4 Cont.: 
3) Inhibition of cell rg owth: 
IL6 Causes inhibition of: 
a) Myeloid leukemic cell line growth. 
b) Breast carcinoma cell line growth. 
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1.6.4: Characteristics and Effects of TNFa: 
1.6.4.1: Discovery of TNFa. 
The name TNFa was coined by Carswell et al (1975) who demonstrated that it was 
cytotoxic against tumour cells. Another group (Caput et al, 1985) investigated a 
substance believed to be an important cause of cachexia and which they called 
cachectin. Cloning and sequencing of cachectin and TNFa cDNAs showed that they 
were identical. 
1.6.4.2: Size and Structure of TNFa. 
TNFa is a protein of relative molecular mass I7kd. It shares 28% homology 
with the cytokine TNFB, with which it also shares biological activity. Both appear 
to act on the same receptors. 
1.6.4.3: Production of TNFa Following Stimulation. 
Principal sources of TNFa are from macrophages, T-cells and natural killer (NK) 
cells (Akira et al, 1990). TNFa can be induced by a variety of stimuli including IL1, 
bacterial endotoxin, lipopolysaccharide (LPS), enterotoxin, toxic shock syndrome 
toxin-1 and other bacterial, viral, or parasitic antigens. TNFa also appears to be able 
to induce its own synthesis (Tracey et al, 1989). 
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1.6.4.4: Effects of TNFa. 
TNFa can stimulate IL1 and IL6 production. It has a wide range of biological 
activities, many of which overlap with those of IL1 and IL6 (see Table 1.5). 
1.6.4.5: Role of TNFa in the Mediation of Acute Inflammation. 
TNF is closely implicated with IL1 in the mediation of acute inflammation. Tracy 
et al (1986) showed that recombinant TNFa administered to rats caused hypotension, 
metabolic acidosis, haemoconcentration and death. The following year Tracy et al 
(1987) went on to show that a similar response was produced when recombinant 
TNF was administered to dogs and that this response was similar to that observed 
with endotoxin. Hesse et al (1988) showed that administration of endotoxin to 
human volunteers caused a peak in TNF concentrations in serum corresponding to 
the onset of fever, rigors, myalgia and headache. The increased TNF concentrations 
were found before any IL I activity could be detected, so Hesse proposed that it was 
the initial inducer of acute inflammatory effects. However, the actual effects may 
be mediated by a synergistic action of IL1 and TNF. 
A summary of the properties of TNFa is given in the table overleaf (After 
Tracey et at, 1989; and Emery and Salmon, 1991) 
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Table 1.5: A Summary of the Biological Properties of TNFa. 
(After Tracey et al, 1989, and Emery and Salmon, 1991) 
1) Induction of Production or Release by TNFa: 
TNF(x stimulates production or release of: 
a) IL 1. 
b) IL6. 
c) GM-CSF. 
d) TNFa. 
e) TNFß. 
f) prostaglandins. 
g) leukotrienes. 
h) PDGF (platelet-derived growth factor). 
i) TGFß (transforming growth factor ß). 
j) platelet activating factor. 
k) cortisol. 
1) adrenaline. 
m) noradrenaline. 
n) glucagon. 
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Table 1.5: A Summary of the Biological Properties of TNF(x Cont. 
Systemic effects of TNF(x: 
a) Mediation of endotoxic shock, with production of hypertriglyceridaemia. 
b) Suppression of lipoprotein lipase in adipose tissue and other cells. 
c) Activation of neutrophils with adhesion. 
d) Endothelial cell toxicity. 
e) Fever. 
f) Induction of the acute phase response. 
g) Leucocyte chemotaxis. 
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1.6.5: Cytokine Interactions and Synergy. 
When considering the properties of the inflammatory cytokines, one of the key 
observations is their apparently common properties and general interaction with one 
another. Under experimental conditions, the effects seen may not be due to the 
cytokine under investigation alone but subsequent action of a different cytokine, or 
concurrent action of another cytokine with the one of interest. Some examples of 
cytokine interactions follow: 
1.6.5.1: Interaction between 11,1 and TNF(x. 
Dinarello et al (1986) demonstrated that recombinant TNFa injected 
intravenously into rabbits produced effects of acute inflammation which were similar 
to those seen with ILL Dinarello and his colleagues also showed that in the case of 
PBMCs TNF was causing IL I release. They suggested a possible synergy between 
IL I and TNF. 
Work by Holtman et al (1987), showed that TNFa receptors were down- 
regulated by IL1 in fibroblasts. TNFa can affect fibroblasts by causing them to 
make IL I, which lowers the number of TNFa receptors on the fibroblast cell surface 
and this in turn lessens the effects of TNFa on the cells. 
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1.6.5.2: Interaction Between TNFa and 116. 
Kohase et al (1986) showed that TNFa could also induce IL6 production. 
This was observed in cultured fibroblasts. 
Recombinant TNF was shown to inhibit the replication of encephalomyocarditis 
virus in fibroblast cells. However this activity could be blocked by administration 
of anti-IL6 antibodies, indicating that the effect was due to the result of IL6, 
probably induced by the TNFa. They also showed that anti-11-6 antibodies could 
enhance the mitogenic effect of administered TNFa on confluent fibroblasts cultured 
in a serum-starved medium, thus demonstrating a possible negative feed-back 
mechanism for fibroblast proliferation involving IL6. Kohase et al then 
demonstrated that there was a complex cytokine network in fibroblasts (1987). 
1: 6.5.3: Interaction between IL! and IL6. 
Van Damme et al (1987 i) demonstrated that ILl stimulates IL6 production 
in fibroblasts, even at very low doses. In a later paper (1987 ii), they confirmed that 
production of IL6 was also stimulated by TNFa. 
47 
1.6.5.4: Demonstration of Synergy Between ILl and IL6. 
Houssiau et al (1988) demonstrated that, while IL6 could stimulate PHA- 
activated T-cells, this activity was dependent on the presence of attendant accessory 
cells. T-cell proliferation was minimal when the activated cells were stimulated with 
IL6 alone. Very similar effects were seen with IL1. Use of ILl and IL6 with the 
activated T-cells, in the absence of accessory cells, produced strong proliferation, 
suggesting synergy. 
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1.6.6: Evidence for the Production of Cytokines by Tumours. 
1.6.6.1: Evidence for the production of ILl by Turnouts. 
Prior to 1986, several authors (Folkman et al, 1971; Folkman and 
Haudenschild, 1980; Lobb et al, 1985) speculated that the spread of a tumour and 
its ability to invade tissue was dependent on both stimulation of blood vessel growth 
to the tumour, and generation of proteolytic activity as a means of invasion. Both 
of these processes involve the breakdown of the patient's extracellular matrix, and 
this is one of the characteristics associated with rheumatoid arthritis. Considerable 
work had already been done to demonstrate the involvement of IL1 in rheumatic 
disease, and so some researchers reasoned that IL I might be involved in tumour 
spread. Therefore, these researchers began to investigate the possibility of IL1 
production by tumours or tumour cell lines. 
Using a liver tumour cell line (Sk hepatoma cell line), Moore et al, in 1986, 
successfully demonstrated the production of a factor very like IL1. It was pyrogenic, 
stimulated collagenase production in skin and synovial fibroblasts, induced bone 
resorption, caused thymocyte proliferation and had a relative molecular mass of 
l8kd. 
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1.6.6.1 Cont.: 
These findings were characteristic of IL I and the substance was therefore 
strongly suspected to be IL 1. The IL 1-like factor was also found (when administered 
to bone resorption assays in-vitro) to be a powerful stimulant of bone resorption, and 
so it was hypothesised by Moore and his colleagues that in-vivo production of IL1 
by tumours in cancer patients could explain the hypercalcaemia often observed in 
these patients. However, this hypothesis was an extrapolation of the results from 
their in-vitro study and they did not examine IL1 production by actual tumours or 
investigate its presence in the serum of tumour patients. 
Sato et al (1987) examined the apparent production of a factor which could 
cause bone resorption by a patient with hypercalcaemia consequent to a squamous 
cell carcinoma of the thyroid. They demonstrated that the factor had the known 
biochemical and biological properties of IL1. An anti-serum to ILl a blocked these 
effects, so the active factor was assumed to be ILla. The results confirmed the 
hypothesis of Moore et al by showing that there was in-vivo production of IL 1a in 
a patient with a tumour, that it could cause bone resorption in in-vitro assays, and 
that the patient displayed hypercalcaemia. In 1988 Sato et al produced further 
confirmation of the association of in-vivo IL1 production with bone resorption and 
hypercalcaemia in a patient with a squamous cell carcinoma of the oesophagus. 
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1.6.6.1 Cont.: 
Using very similar methods to those of Sato et al, Freid et al (1989) 
demonstrated the production of IL I in patients with carcinomas (they studied 
squamous cell carcinoma cell lines derived from patients with tumours of the tongue 
or facial epidermis) but without hypercalcaemia. 
Work was also carried out to investigate whether ILI might benefit the 
tumour. On et al (1988), working with cultured human endothelial cells in vitro, 
showed that medium from these cell cultures contained a substance which was an 
attractant for tumour cells. They found that secretion of this agent could be 
correlated with mRNA expression for ILI in the cells, and that it had the 
biochemical properties of IL I. Indeed, their results could be mimicked by the 
administration of human recombinant ILI ß, and the effect was found to be dose 
dependent. This suggested that IL I might be involved in promoting tumour cell 
migration with formation of metastases. 
Dejana et al (1987) showed that IL I could affect the vascular endothelium, 
as well as being produced by it. IL1 seemed to make the endothelium more adhesive 
to tumour cells, allowing them to stick to it. The effect was both time and dose 
dependent. They postulated that it could cause the localisation of metastases. 
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1.6.6.1 Cont: 
Giavazzi et al (1990) showed a definite augmentation in the formation of 
metastases in nude mice with human melanomas (the mice were infected with the 
human melanoma cell line A375M). The effect was concentration dependent and 
short lived. They postulated that IL1 production might contribute to the malignant 
behaviour of tumours by favouring the implantation of tumour cells at selected sites. 
The effect of ILI was apparent even though it was injected, therefore the effect was 
not due to any local production at a specific site. Circulating IL I from the tumour, 
therefore might have the same effect of contributing to the formation of metastases 
in general. 
Further evidence for the production of IL1 by tumour cells came from a major 
study by Miyauchi et al (1988), who examined medium, taken from 64 malignant 
cell lines, for IL1 activity. Analysis was by the murine thymocyte proliferation 
assay, backed up by biochemical characterisation to check that the active factor 
causing the results in the assay was IL 1.16 cell lines showed high IL I activity 
including glioblastoma, oral squamous cell, lung squamous cells, hepatoma, 
pancreatic cancer, cervical cancer and malignant melanoma. 
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1.6.6.1 Cont: 
Some other cell lines, including the breast cell line MCF-7 and the bladder cell line T- 
24, produced small amounts of IL I 
Malignant melanoma proved useful in the study of IL I production. Following 
the work of Miyauchi et al, Kock et al (1988) examined the production of IL1 by 
malignant melanoma cell lines. Most of the work was carried out using a combination 
of bioassay, and biochemical techniques. In addition molecular biological techniques 
were used, one of the earliest examples of this approach. Northern blotting confirmed 
the existence of messenger RNA for IL Ia in the cells. 
Further molecular biological work (Shabon et al, 1989) was the first to confirm 
that the genes in malignant melanoma cells expressing ILIa were the same as those 
expressed in the "natural" source of macrophages. The genes for IL Ia and IL IB 
were cloned and sequenced in the malignant melanoma cell line studied (WM1158), 
the first time this had been done in tumour cells and provided strong evidence that 
tumour cell lines could produce IL1. 
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1.6.6.1 Cont.: 
Work has continued to investigate the extent of IL1 production by various 
types of cells. For example, in 1992, Li et al observed that human ovarian cell lines 
cultured, in vitro, expressed genes for both IL 1a and IL 1 ß. They found that 5 
different ovarian cancer cell lines expressed the genes for IL1 a and ß constitutively. 
This expression was also found in cells harvested from ascitic fluid of patients with 
ovarian cancer, thus indicating the possibility of ILl production in vivo as well as 
in vitro. 
1.6.6.2: Evidence for the production of lL6 by Tumours. 
As with IL1, the effects of IL6, or those which could be caused by its secretion, are 
seen in patients with certain tumours. This, and evidence for IL6 production by 
some cell lines, created interest in its possible use as a tumour marker. 
Subsequently, studies have been undertaken to determine if it is produced by 
tumours. 
Tabibzadeh et al (1989), in a wide-ranging study, used antibodies to IL6 to examine 
any evidence of its production by certain solid tumours. This was achieved using 
immuno-staining on frozen sections of freshly removed tumours with the anti-IL6 
antibody; a second biotin-labelled antibody was used to detect the first. 
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1.6.6.2 Cont.: 
A wide variety of tumours was examined. IL6 was detected in neoplastic 
(cancerous) elements in primary squamal cell carcinomas of colonic, ovarian, and 
endometrial origin, metastatic adenocarcinomas, and lymph nodes and cells of soft 
tissue tumours such as leiomyosarcoma. Poorer staining was present in the other 
tissues examined. However, it was sufficient to show that most tumours of epithelial 
or mesenchymal origin displayed the presence of IL6. 
The presence of a pool of IL6 seemed to be a general feature of neoplastic 
tissues, backing up and extending the results of previous work which showed the 
presence of IL6 in cardiac myxoma (as seen by Hirano et al in 1987). Tabibzadeh 
et al postulated that such a generalised production of IL6 by tumours might suggest 
that IL6 plays a major role in the modulation of host-tumour interactions both locally 
and systemically, by altering the physiological, biochemical and immunological status 
of the host. 
Miki et al (1989) examined renal carcinomas and found that when these 
carcinomas were grown in vitro, like many cell lines, they required foetal calf serum 
(FCS) for growth. However they found that if recombinant human IL6 was supplied 
to the cultures, (in the absence of FCS) the cells could grow. 
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1.6.6.2 Cont.: 
Miki et al suspected that IL6 was needed as a. growth factor for the cells and that it 
was being produced by the cells in response to another factor in the FCS suggesting 
that IL6 is an autocrine growth factor for the cells. Using immuno-staining for IL6, 
it was found that renal carcinoma cells were producing IL6. Analysis of extracted 
mRNA from the cells by northern blotting showed the presence of mRNA for IL6. 
Use of another anti-11-6 antibody administered to the cells in culture inhibited their 
growth. 
The evidence seemed to support the theory that, in vitro, IL6 was an autocrine 
growth factor for renal carcinomas. However, at that time, there was no evidence 
of production of IL6 in vivo in patients with renal carcinomas, although patients 
with these tumours often showed clinical symptoms, such as elevated concentrations 
in serum of acute phase proteins, which could be caused by the effects of IL6. 
Takenawa et al (1991) used northern blotting to examine whether IL6 was 
present in fresh tissue taken, immediately following surgery, from patients with renal 
carcinoma. A semi-quantitative technique was used to compare results with those 
taken from non-neoplastic tissue from other patients. 
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1.6.6.2 Cont. 
10 out of 43 tumour samples displayed as much as a 40-fold increase in IL6 mRNA 
expression as compared to the control tissue (normal renal glomeruli, mesangial cells, 
and vascular endothelium express low concentrations of IL6). Immuno-staining of 
the tumour tissue indicated that it was not normal cells producing the IL6, but the 
tumour cells themselves. Following on the ideas of Miki et al, they also looked for 
mRNA expression for the IL6 receptor. If 1L6 was an autocrine growth factor then 
the renal carcinoma cells would have to express the IL6 receptor as well as 
expressing IL6. 
Northern blotting gave a negative result for presence of the receptor, but use 
of the very sensitive polymerase chain reaction to amplify cDNA prepared from the 
extracted mRNA did show that the renal carcinoma cells expressed the IL6 receptor. 
Takenawa et al also examined the relationship between the production of IL6 
in patients with renal carcinomas and the clinical conditions which the patients 
displayed. They showed that patients with tumours showing enhanced IL6 
production had apparently higher concentrations of C-reactive protein in serum and 
a higher erythrocyte sedimentation rate, though these were not statistically 
significant. 
57 
1.6.6.2 Cont.: 
The incidence of lymph node metastases was significantly increased in patients with 
enhanced concentrations of IL6. Thus, the findings and hypotheses of Miki et al 
were verified and it appeared likely that IL6 could make a good marker for renal 
carcinoma. 
Interest has also been shown in the possibility of IL6 being a marker in other 
cancers, and in particular those which are difficult to monitor or diagnose by other 
means. In ovarian carcinoma, as has been previously mentioned, the marker CAI 25 
has recently been characterised. However, IL6 has been examined as a possible 
marker also. Watson et al, in 1990, demonstrated that primary cultures from ovarian 
tumours, and 3 ovarian cell lines, could secrete IL6. In 1991, members of the same 
team, in a paper by Berek et al, looked at IL6 concentrations in serum from 
patients with ovarian carcinomas to determine if they would correlate with the 
disease state of the patients. A bio-assay was used to detect the IL6 (using the 
MH60. BSF-2 cell line, an IL6-dependent murine hybridoma cell line). 
58 
1.6.6.2 Cont.: 
IL6 concentrations in 90 separate samples of serum were measured. In those 
patients with macroscopic disease, 16 out of 21 patients had significantly raised 
concentrations of IL6 compared to the concentrations measured in the serum of 
normal women used as controls. 
Out of 9 patients with bulky tumours. S had significantly raised 
concentrations, and 8 out of 12 patients with residual disease also had high 
concentrations. There was also a definite correlation between raised CA 125 
concentrations and high IL6 concentrations in 12 out of 14 patients. Studies of IL6 
concentrations in serum over a period of 3 to 4 months showed that in 9 out of 16 
patients, concentrations of IL6 were seen to rise. This increase was also seen to 
correlate with tumour progression. There also appeared to be a link between IL6 
concentrations in serum and patient survival rate, the patients with higher IL6 
concentrations being less likely to survive. These data suggest that, as with renal 
carcinoma, IL6 might be a useful marker for the monitoring of ovarian carcinoma. 
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1.6.6.2 Cont.: 
Meyers et al (1991) investigated bladder carcinoma to see if IL6 expression 
could correlate with prognostic factors. The treatment of bladder carcinoma is 
dependent on the accurate assessment of the malignant potential of the tumour. 
Usually this is determined by staging (assessing the extent of invasion of the 
surrounding tissue by the tumour) and histological categorisation (low grade versus 
high grade. Meyers et al used polymerase chain reaction (PCR) amplification of 
prepared cDNA transcripts of extracted mRNA (this technique is discussed in section 
2), which has the particular advantage of allowing probing for several gene products in 
the same sample simultaneously. All of the ex-vivo transitional cell carcinomas, one 
squamous carcinoma and 2 transitional cell carcinoma cell lines (including the cell line 
T-24) expressed the majority of HLA genes. All of the samples and cell lines 
expressed the IL6 receptor. One of the cell lines and all of the high grade tumours 
expressed mRNA for IL6. 
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No useful correlation of IL6 expression with prognostic or diagnostic factors 
was demonstrated in the study and no investigation was undertaken to examine if the 
detected IL6 expression was due to the carcinoma cells or due to infiltrating cells in 
the tumour (e. g. macrophages). The expression of the IL6 receptor and IL6 in high 
grade transitional cell carcinomas suggested that in these too, IL6 might be an 
autocrine growth factor, as is the case with renal cell carcinomas. 
As with IL 1, efforts have been made to link IL6 to clinical conditions often 
observed in cancer patients, such as cachexia. This involves depletion of muscle and 
fat, anorexia, asthenia, hyperglycaemia and anaemia and is often an important 
contributor to the death of patients. 
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1.6.6.2 Cont. 
As will be examined later, efforts have been made to link cachexia with 
tumour necrosis factor (TNF) (see 1.6.6.3. ) This has included studies with animal 
models, usually in rats or mice. Strassman et al (1992) set up an animal model of 
cachexia in mice. They used a cell line derived from murine colon 26 
adenocarcinoma, an undifferentiated tumour induced by a carcinogen, which caused 
cachexia. However, rather than examining any evidence for TNF production, they 
measured IL6 concentrations in serum in the mice, using the B-9 bioassay. They 
found a definite correlation between concentrations in serum of IL6 and the state of 
the cachexia in the mice. 
When the tumours were resected, the concentrations of IL6 in serum fell (thus 
indicating that the tumours were the source of the IL6) and the mice also began to 
gain weight. That the IL6 was involved in the cachexia was confirmed when it was 
observed that administration of a monoclonal antibody to IL6 to the mice caused 
significant suppression of the development of cachexia. Whether this is also true 
in humans remains to be demonstrated. 
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1.6.6.3: Evidence for the production of TNFa by Tumours. 
The first significant investigation into TNFa production in human cancer patients 
was undertaken by Balkwill et al (1987). In an attempt to demonstrate that TNFa 
was responsible for cachexia, they assessed 226 samples of serum taken from cancer 
patients, using a sensitive enzyme linked immuno-sorbant assay (ELISA). Samples 
of serum were also taken from normal individuals to provide a control group. 50% 
of the samples from cancer patients yielded detectable TNF, but TNFa was found 
in only 3% of the control group. Of 39 samples from patients with tumours, 
who displayed no clinical symptoms of cancer, 18% had detectable concentrations 
of TNFa. A greater proportion of samples were TNF-positive in patients with 
ovarian or oat-cell carcinomas (69 and 67% respectively), while in lymphomas 26% 
were positive. 
In the same study, efforts were also made to identify the source of the TNFa. 
Northern blotting of mRNA extracted from peripheral blood mononuclear cells and 
from tumour samples taken from patients with colorectal carcinomas known to have 
TNFa in serum was carried out, using a probe for TNFa. Peripheral blood 
mononuclear cells taken from normal individuals were also probed. TNFa mRNA 
was found in 8 out of 11 samples of peripheral blood mononuclear cells from the 
patients with cancer, but in only 1 of 8 samples from the normal group. 
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1.6.6.3 Cont.: 
TNFa mRNA was detected in 2 out of 6 colorectal tumours examined. Thus 
it appeared that while the majority of the TNFa was from peripheral blood 
mononuclear cells, probably in response to the tumour, some tumours may produce 
TNFa. Balkwill et al proposed that circulating TNF was responsible for the cachexia 
seen in some patients. 
Further evidence for the production of TNFa by tumours in vitro was provided in 
a later study (Takayama et al, 1990). Takayama and his colleagues used immuno- 
staining to examine evidence of TNFa in ovarian carcinomas and found that of 20 
samples examined 16 were positive for TNFa. In-situ hybridisation was also carried 
out and confirmed the immuno-staining findings with the presence of TNFa mRNA 
being detected in the tumour tissue. Subsequently, Roby et al (1991), demonstrated 
that TNFa could be expressed in normal ovarian tissue in vivo. 
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1.6.6.3 Cont.: 
In vivo studies were still unclear however. The research by Balkwill et al 
showed that TNF could be produced by peripheral blood mononuclear cells in cancer 
patients. Ishi et al (1990), detected TNF(x from a pleural effusion of a patient with 
lung cancer. The fluid could inhibit growth (in vitro) of lung tumour cells taken 
from the same patient. The origin of the TNF was suspected to be monocytes or 
macrophages. In another study, by Ikemoto et al (1989), monocytes were shown to 
produce TNF in patients with bladder carcinomas. 
In vitro studies were also carried out to examine if cell lines could produce 
TNFa. Spriggs et al (1988) demonstrated that some tumour cell lines could produce 
TNFa. 2 out of 4 ovarian cell lines, and I out of 3 lung tumour-derived cell lines 
expressed mRNA for TNFa, as detected by Northern blotting. 
These results were supported by Kronke et al (1988), who examined 17 
tumour cell lines of various origins and found (again by northern blotting to show 
expression of TNFa mRNA) that 8 cell lines could express TNFa without any 
external stimulus (i. e constitutively). Probing for TNFß, Kronke and his colleagues 
found that 5 of the 8 also displayed TNFß production. Of 9 cell lines not showing 
constitutive expression, 5 were induced to express TNFa if stimulated by phorbol 
ester and/or various cytokines. 
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1.6.6.3 Cont: 
The cell lines displaying constitutive TNFa mRNA expression included those 
derived from solid tumours, and myelomas. Significantly, TNFß was expressed only 
by cell lines of myeloid origin. 
Kronke et al also proposed that TNFa could have a beneficial effect on some 
tumours (presumably those resistant to its cytotoxic effects), especially with regard 
to the formation of metastases. They proposed that the mechanism for this might be 
promotion of growth of blood vessels to the tumour and possibly also promotion 
of tumour invasion. Kronke et al further proposed that TNF production could be 
involved in the hypercalcaemia observed in some patients with myeloma. 
Rosen et al (1991) found that TNFa could stimulate the migration of epithelial 
tumour cells in vitro and promote the invasion of several tumour cell lines through 
reconstituted basal membrane, giving support to the ideas expressed by Kronke et al. 
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1.6.6.3 Cont. 
Work also continued on the link between TNFa and cachexia. Much of this 
was carried out on rats. Stavroff et al (1989), using a bio-assay to determine the 
concentration of TNF in the serum of sarcoma-bearing rats, established a correlation 
between TNFa concentrations in the serum and tumour burden. There was also an 
inverse relationship between the concentration of TNF and rate of food intake and 
body weight change. After resection of the tumours, TNF concentrations in serum 
fell to undetectable levels, indicating that the TNF production was due to the 
presence of the tumour, even if that was not necessarily its source. 
However, animal models cannot always be relied on to give results predictive 
of human disease. In a similar study carried out in humans, Knapp et al (1991) 
examined the relationship between weight loss and TNF production in patients with 
advanced breast cancer. They found that TNFa was present in significant amounts 
in the serum of all the patients, the concentrations being significantly higher in 
patients who had lost weight (one of the symptoms of cachexia). Concentrations of 
TNFa were also seen to increase significantly as the patients' disease progressed. 
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1.7: Aims of the Research Presented in this Dissertation 
The original aim of the research presented in this dissertation was to study the 
synthesis of IL1 a, ILl S. IL6. TNFa, and TNFS3 by tumour cells, and to develop 
methods for the detection of cytokines and their mRNA in primary samples of 
tumours. None of these cytokines could be considered as tumour markers if they 
were not produced by a suitable variety of tumours, or indeed by any types of 
tumour. It was not the aim of the research to develop any of the cytokines as 
tumour markers, but it was hoped that the results of the work would indicate which 
cytokines (if any) could be developed as markers in future studies. 
The types of tumour used in the study would be determined by a number of 
criteria, including: availability, frequency, and ease of collection of tumour samples, 
and as wide a variety of different tumours as possible would be collected. It was 
also decided to avoid collecting certain types of tumour which were already known 
to produce the cytokines of interest, in favour of those whose cytokine production 
profiles (in 1989) were largely unknown. 
68 
1.8: Plan of Investigation of this Present Study. 
At the time of commencement of this investigation in October 1989, very little 
was known about the production of IL 1 a, IL 1 ß, IL6, TNFa, and TNFß, by tumour 
cells themselves. Those investigations that had been undertaken had used for the 
most part methods which were non-specific. Only a few used more specific methods 
based on molecular biology techniques (examination of cytokine mRNA production), 
or immunological techniques (immuno-histology or immuno-assay of the cytokine 
polypeptide). In addition, much of the work had been carried out on cell lines or 
primary explants of tumours grown in culture. It was therefore decided that the 
investigations that are now reported here would examine the production of these 
cytokines in samples of solid tumours taken from patients as soon as possible 
following surgery. 
The studies were performed in three phases, as follows: - 
a) Methods would be verified in studies on tumour cell lines whose cytokine 
production profile was known. The cell lines would also enable some other 
experiments which would be difficult to perform with the tumour samples 
themselves, e. g. to examine whether any of the cytokines were growth factors for the 
cell lines (and so possibly also for the tumours). 
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b) Experiments would then be performed to explore cytokine production in the solid 
tumour samples themselves. 
i) By examining cytokine mRNA production in the tumours. 
ii) By using immuno-histology to confirm that tumours were producing 
cytokine polypeptides. 
c) The medical records of patients donating tumour samples would be checked to 
assess if any patients displayed clinical symptoms or conditions which could be 
attributed to production of relevant cytokines by the tumour. 
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Chapter 2: Methods. 
2.1: List of Reagents and Materials. 
From BDH Ltd. Poole, Dorset, U. K.: 
Chloroform, reagent grade 
Ethanol, reagent grade 
Formalin 
Acetone 
Xylene 
Paraffin wax 
Sodium Acetate, 3M (pH 5.2) 
From Biogenesis Ltd.. 12 Yeoman's Park, Bournemouth. U. K.: 
RNA Sol solution 
From Boehringer Mannheim Gmbh. 
10mM deoxynucleotide mix (equal mixture of deoxyadenosine trisphosphate, 
deoxythymidine trisphosphate, deoxycytosine trisphosphate, and deoxyguanosine 
trisphosphate) 
Restriction Enzymes: Eco RIE. C. no. 3.1.27.1 
Hinf I E. C. no. 3.1.30.1 
Msp I E. C. no. 3.1.30.2 
Taq polymerase, E. C. no. 2.7.7.7 
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Taq Polymerase buffer (Tris 100mM, MgC12 15mM, KCI 500mM, gelatin l mg/ml, 
ph 8.3) 
From FMC Ltd., Sittingbourne , U. K.: 
Seakem agarose 
From Gibco Ltd.. Renfrew Road, Paisley U. K.: 
10mM deoxynucleotide mix (equal mixture of deoxyadenosine trisphosphate, 
deoxythymidine trisphosphate, deoxycytosine trisphosphate, and deoxyguanosine 
trisphosphate) 
OA M dithiothreitol (DTT) 
Foetal calf serum 
Glutamine 
2-Mercaptoethanol 
Oligo dT primer 
Penicillin/ streptomycin solution 
10x reverse transcriptase synthesis buffer 
RNase H, E. C. no. 3.1.27.1 
RPMI 1640 cell culture medium 
RPMI 1640 cell culture medium, phenol red free 
Superscript TM reverse transcriptase, E. C. no. 2.7.7.7 
Trypsin 
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From Glasgow University Biochemistry Department, Glasgow, U. K.: 
Oligonucleotide primers 10mM 
From Janssen Biochemica: 
Hybridoma Growth factor/ crude IL6 
From Nat. Institute of Biological Standards and Control Potter's Bar U. K.: 
Anti- IL1 antibody (Sheep) 
Anti- IL6 antibody (Goat) 
From Scottish Antibody Production Unit. Law Hospital. U. K.: 
Anti- CD8 Antibody (Mouse) 
Anti- CD 14 Antibody (Mouse) 
Anti- CD21 Antibody (Mouse) 
FITC-Conjugated Anti-Mouse Antibody 
From Sigma Ltd.. Fancy Road, Poole, Dorset, U. K.: 
Diazo-bicyclo 2,2,2, octane (DABCO) 
Diethylpyrocarbonate (DEPC) 
Ethidium Bromide 
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FITC-Conjugated anti-sheep antibody 
FITC-Conjugated anti-goat antibody 
Alkaline Phosphatese-Conjugated anti-sheep antibody 
Alkaline Phosphatase-Conjugated anti-goat antibody 
Fast Red'm Alkaline Phosphatase detection system 
Gelatin 
Isopropanol 
MTT dye 
Phenol, molecular biology grade 
Triton X-100 detergent 
From Dept. of Pathology. Western Infirmary. GGlasgow. U. K.: 
Haematoxylin 
Eosin 
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2.1 Cont.: Prepared Reagents 
Tris-borate buffer (x5 stock Solution): 
0.089 M Tris-borate: 54 g tris base 
0.089 M boric acid: 27.5 g boric acid 
0.002 M EDTA: 20 ml 0.5 M EDTA (pH 8.0) 
made up to 11 with distilled water. 
Sample Loading Buffer (x6 stock solution): 
0.25% bromophenol blue, 40% (w/v) sucrose in distilled water 
(Keep at 4°C) 
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2.2: RNA Extraction. 
2.2.1: Introduction. 
In initial experiments to extract mRNA from cells or tissues the guanidinium 
isothiocyanate/ phenol/ chloroform method developed by Chomczynski and Sacchi 
(1987), and utilising locally prepared reagents, was employed. Testing of the 
extracted material prepared by this method resulted in only degraded mRNA being 
found. It was thought that this was due to either one of the reagents being 
contaminated, or contamination of glassware with RNAse, but the cause was not 
definitely established. Subsequent experiments, using commercial RNAsol 
(Biogenesis Ltd. ), which is a ready-mixed guanidinium isothiocyanate/phenol 
solution, and use of a slightly adapted protocol using isopropanol to precipitate the 
RNA instead of ethanol, did provide intact mRNA. All glassware used with this 
protocol was treated in a similar manner to that in experiments with the locally 
prepared reagents. 
2.2.2. Method employed for mRNA Extraction: 
(1) The tissue sample was frozen (-70°C). A portion of approximately 1 cm3 was 
removed with a scalpel, and placed in a small petri dish. The remainder of the 
sample was then plunged into liquid nitrogen to ensure it remained fully frozen 
before being returned to storage in the -70°C freezer. 
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2.2.2 Cont. 
(2) I ml of RNAso1 was added to the sample on the dish, thus ensuring that the 
tissue would be in RNAsol as it thawed. The tissue was then chopped into as small 
pieces as possible and pipetted into a sterile 2m1 polypropylene microcentrifuge tube 
(Sarstedt Ltd. ) together with all the liquid. A further 0.5m1 of RNAso1 was then 
used to wash out the petri dish and this wash added to the tube. 150µl of 
chloroform was added and the tube left to stand upright in ice for 5 min. 
(3) The tube was then centrifuged in a pre-cooled refrigerated microfuge at 10000g 
for 15 min. The contents of the tube were now identifiable as three layers, a clear 
aqueous upper layer, an interface layer of solid material, and a lower blue organic 
layer. The top (aqueous) layer was carefully removed, without disturbing the layers 
below, and placed in another 2m1 microfuge along with an equal volume of cold 
isopropanol (taken from -30°C freezer and used immediately). The tube was left to 
stand on ice for 15 min and then centrifuged using the same conditions as before. 
(4) The resulting precipitate was drained carefully, washed twice in a mixture of 75% 
ethanol, 25% DEPC treated water, and centrifuged as before, but for 10 min between 
each wash. The sample was then air-dried in the tube, in the flow hood at room 
temperature, and the resultant pellet of material dissolved in 104gl of DEPC treated 
water. 
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2.2.2 Cont. 
(5) 4µl of this solution was removed and placed into a fresh microfuge tube and 
396µl of DEPC water added to give a total volume of 400µl. The absorbance of this 
solution was then measured on a spectrophotometer with a deuterium light source, 
previously blanked with plain DEPC water, at 260 and 280 nm, using suitable quartz 
cuvettes. 
The ratio of Absorbance at 260 nm / Absorbance at 280 nm is indicative of the 
purity of the RNA. A ratio of >1.8 indicates good purity of RNA, though in practice 
samples with ratios of as low as 1.3 were still found to yield RNA pure enough to 
be reverse transcribed. The absorbance at 260 nm was used to calculate the yield 
using the principle that an absorbance value of 1 optical density (4. D. ) at that 
wavelength equals 0.04 mg of RNA, i. e.: 
RNA YIELD (mg/ml) = Absorbance at 260 nm x 0.04 x 100 
(x100 because the sample is a 1/100 dilution ie. 4µl/ 400µ1) 
(6) 300µl of absolute alcohol was added to the remaining 100 µl of stock sample 
prepared in (4), and the sample stored at -70°C until needed. 
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2.2.3: Explanation of Method. 
The guanidinium isothiocyanate in the RNAsol is a potent inhibitor of RNAse and 
causes immediate cell lysis and protein denaturation. The phenol in the solution 
deproteinises the nucleic acids. The added chloroform acts as an organic solvent. 
The extraction process, after addition of the RNAsol and chloroform to the 
sample and centrifugation (see method for details), results in the creation of an upper 
clear aqueous layer containing RNA, an interphase layer of proteins, and a lower 
blue layer with DNA. The aqueous layer is transferred into a separate tube and the 
RNA precipitated using isopropanol. RNA is more insoluble in isopropanol than 
ethanol, resulting in a faster precipitation. The RNA must be washed in alcohol 
prior to being used for any purpose to remove contaminating traces of phenol or 
chloroform. 
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2.2.4: Precautions Necessary for Working with RNA. 
Stringent precautions have to be observed when working with RNA due to the 
danger of contamination by the enzyme RNase which can rapidly break down any 
RNA that is present. This enzyme is very stable and it is only broken down by 
extreme conditions e. g. a temperature in excess of 180°C. It is also very prevalent. 
All work involving RNA has to be carried out in a laminar flow hood (to prevent 
airborne contamination) and gloves have to be worn at all times as RNase can be 
secreted in sweat. Glassware has to be baked at 250°C for at least an hour but 
where possible, it is better to use sterile disposable plastics. All aqueous solutions 
must be made up with distilled water treated with diethyl-pyrocarbonate (DEPC 
water) which breaks down RNase. Autoclaving is necessary to remove traces of 
DEPC and to sterilise the solution. Microfuge tubes must be soaked in DEPC water 
for at least an hour and then autoclaved. 
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2.3: Reverse Transcription of RNA into cDNA. 
2.3.1: Introduction. 
Reverse transcription was used to convert the extracted mRNA into its 
corresponding complementary DNA, or cDNA, prior to any further analysis. RNA 
is unstable and prone to digestion by RNAse, a very common enzyme. It is also 
single stranded, rather than double stranded and often forms loops due to 
complementary base pairing. It is therefore best to convert it into a corresponding, 
and more stable, cDNA. The method for doing this uses the enzyme, Reverse 
Transcriptase. Oligo dT primer was used to prime the reaction as it ensures 
amplification of mRNA, which contains a poly-adenylated tail. 
Enzyme and Oligo dT primer were supplied in kit form with all the necessary 
reagents. The manufacturer's protocol was used without modification and the kit 
used was from Gibco BRL. 
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2.3.2: Method for Reverse Transcription. 
2.3.2.1: Extraction of mRNA from Storage in Alcohol. 
The following method was performed to retrieve mRNA from storage in alcohol 
prior to reverse transcription (It was not performed where reverse transcription was 
carried out immediately following RNA extraction). 
(1) A volume of the stock solution was removed so that it contained approximately 
5µg of RNA, and placed in an RNAse-free 0.5 ml microfuge tube (see 2.1.2. p61) 
To this was added 1 /10th of the volume of 4M ice-cold sodium acetate (taken 
from the -30°C freezer and used immediately) and the tube was left to stand at -70°C 
for 15 min. 
(2) The tube was then centrifuged at 10000g for 15 min at 4°C in a refrigerated 
microfuge. 
(3) The resulting pellet (often invisible or only a smear) was washed twice in a 75% 
ethanol, 25% DEPC water mixture (centrifuged as in (2), but for 10 min). It was 
then air dried in the tube, in the laminar flow hood at room temperature, and 
dissolved in 13µl of DEPC water. The sample was now ready for reverse 
transcription. 
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2.3.2.2: Reverse transcription. 
(1) 1 µ1 of oligo dT primer (provided in the reverse transcription kit) was added to 
the tube, and the tube heated to 70°C in a Hybaid thermal reactor for 10 min. 
(2) The contents were collected by centrifugation for 15s at 10000g and quick-chilled 
on ice. The following were then added in order: 2µl of l Ox synthesis buffer, 1µl of 
10mM dNTP mix, 2µl 0.1 M DTT, l µl of SUPERSCRIPT RT reverse transcriptase 
(EC no. 2.7.7.7) 
(3) The mixture was mixed gently and collected by brief centrifugation (as in 2) and 
left at room temperature for 10 min. It was then heated to 42°C in the thermal 
reactor, and left to incubate for 50 min. The reaction was terminated by incubating 
the tube at 95°C for a further 10 min. 
(4) The tube was cooled on ice for 10 min, and the contents collected by brief 
centrifugation (as in 2). 1 µl of RNase H (E. C. no. 3.1.27.5) was added to the tube 
and incubated at 37°C for 20 min. The contents of the tube were collected by brief 
centrifugation (as in 2) and 79µl of DEPC water added to give a final volume of 
100µl. The sample was stored in the fridge at 4°C. 
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Table 21 Thermocycler Programme for Reverse Transcription *. 
Step 1) 70°C for 10 min 
Step 2) 42°C for 50 min 
Step 3) 90°c for 5 min 
if adding RNase H: 
Step 4) 37°C for 20 min 
(* using a Hybaid T2 thermocycler) 
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Figure 1: Illstr ation of the Principle of PCR. 
The figure shows repeated cycles of DNA denaturation, oligonucleotide primer annealing, and 
elongation with DNA polymerase, which results in an exponential increase in the DNA flanked 
by the primers. 
2.4: Polymerase Chain Reaction Analysis of cDNA for Cytokine 
Expression. 
2.4.1: Theory and Background to the Polymerase Chain Reaction. 
The polymerase chain reaction (PCR) is one of the most powerful new 
molecular biology techniques. Originally developed by Saiki et al (1985), and Mullis 
et al (1986), PCR is used to amplify, many times, a segment of DNA (or cDNA, 
complementary DNA made by reverse transcription of mRNA) that lies between two 
regions of known sequence. Two oligonucleotide primers, usually of different 
sequences, which are complementary to the known flanking regions of the sequence 
to be transcribed, are used together with the key enzyme, a DNA polymerase. 
Figure 2.1 opposite illustrates the process: 
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2.4.1 Cont.: 
Firstly, the template DNA is thermally denatured by heating at approximately 
90°C for 2 to 3 min, and then it is hybridised with the primers. The DNA 
polymerase extends each primer to give a copy of each of the original strands. 
The 
primers are designed so that the products of each extension have overlapping ends. 
This means they can act as new templates to be primed and extended by the 
opposing oligonucleotide in a new round of synthesis and this is repeated many 
times. The number of copies made of the region of interest defined by the primers 
increases exponentially as a function of the number of cycles. Each cycle of the 
reaction can be completed in a few minutes, and therefore in three to five hours a 
sequence can be amplified from 3x105 to 2x107 times. Importantly, the majority of 
strands synthesised during the PCR are the same length, as defined by the distance 
between the binding sites of the two primers, so that each product can be visualised 
as a discretely migrating band by agarose gel electrophoresis. 
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2.4.1 Cont.: 
The sequence chosen for amplification often has one or more restriction 
enzyme sites built into it. This means that the identity of the amplified product can 
be checked by restriction enzyme digestion following the PCR process. 
The first protocols for PCR used, as the polymerase, the Klenow fragment of 
E. coli DNA polymerase, which was not stable at the high denaturing temperature 
of the reaction (95°C) and so had to be added after the denaturing step in each round 
of the reaction (Saiki et al , 1985; Mullis et al, 1986) This has been replaced by a 
polymerase from Thermus aquaticus (Taq DNA polymerase), which is stable at 95°C, 
and can survive at least 40 cycles (Chien et al, 1976). This enzyme can be added 
entirely at the start of the reaction and needs no replacement, allowing the reaction 
to be mechanised using a programmable thermocycling machine. It also increases 
the specificity of the PCR, while decreasing the amount of starting material that is 
required (Saiki et al 1988). PCR can be used to amplify DNA from almost any 
source, including cDNA prepared from extracted mRNA. 
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2.4.2: Artifacts Which Can Occur in PCR. 
PCR, no matter how well performed, can produce artefacts. The most 
common of these are primer dimers. While primers are chosen to minimise the 
possibility of cross-hybridisation, dimers can be formed. Since dimers are of small 
size, they can easily be distinguished from products, which have a much larger size. 
In an agarose gel, which separates DNA or RNA depending on the mobility of each 
fragment when a current is passed through the gel, the primer dimers travel very far 
along the gel (beyond the bromophenol blue dye front) but the products travel less 
far as they are much larger and are retarded by the gel. 
Other artefacts can occur e. g. nucleotide or degraded cDNA fragments. These are 
also of very small size and can be distinguished from products in the same way as 
primer dimers. 
While care in choosing primer sequences which are intron-spanning should 
eliminate the chances of genomic DNA being amplified, this can occur. Genomic 
DNA products amplified are of large size and appear towards the bottom of agarose 
gels (near the sample wells) The presence of artefacts means that the identity of 
each PCR product has to be checked by comparing its observed size to the expected 
size and by restriction enzyme digestion. 
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2.4.3. Method used for PCR: 
2.4.3.1: Precautions Necessary to Prevent Contamination by Extraneous DNA. 
The PCR method is very vulnerable to false results caused by accidental 
contamination by extraneous DNA. Stringent precautions have to be taken as 
follows: 
1) Gloves to be worn at all times and changed frequently. 
2) The reaction should be carried out in a good laminar flow hood, preferably a class 
II, with an ultraviolet light fitted, which is washed with a detergent (Decon) and then 
a 70% alcohol, 30% DEPC water mixture before use. 
3) The following are then placed in the hood: 
(i) Two pipettes, thoroughly cleaned with Decon/ alcohol (200µl and 20 µl sizes). 
(ii) A vial of sterile water used only for PCR. 
(iii) A new box of standard yellow pipette tips. 
(iv) A new container of 0.5 ml microcentrifuge tubes, previously autoclaved. 
(v) A marker pen 
(vi) Reaction components (buffer, etc. ) 
(vii) Oligonucleotide primers. 
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2.4.3.1 Cont.: 
The Taq Polymerase enzyme, which performs the reaction, is kept in the freezer (- 
20°C) until required for use. The U. V. light is switched on and the contents of the 
hood exposed for at least 20 min. U. V. light cross-links any DNA which may be 
present, preventing it from being a possible contaminant. 
2.4.3.2: Method employed for PCR 
The reaction volume used was 50µl. The following reagents were used: 
1) dNTP mixture: An equal mixture of the nucleotides deoxyadenosine 
tnsphosphate (dATP), deoxycytosine trisphosphate (dCTP), deoxyguanosine 
trisphosphate (dGTP), deoxythymidine trisphosphate (dTTP) each at a concentration 
of 10mM. (Nucleotides supplied by Boehringer Mannheim Gmbh) 
2) 1Ox Reaction buffer (supplied with the Taq polymerase): Tris 100mM, MgCl2 15 
mM, KCl 500mM, gelatin lmg/ml (pH 8.3) 
3) Oligonucleotide primers, ready mixed at a concentration of 10µM (obtained from 
Glasgow University Biochemistry Department) 
4) Taq DNA polymerase (E. C. no. 2.7.7.7) (Boehringer-Mannheim Gmbh) 
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2.4.3.2 Cont.: 
The reaction was performed as follows: 
1) 0.5µl microfuge tubes were labelled appropriately and the following added to each 
tube: 
4µ1 of dNTP mix 
5µl l Ox reaction buffer 
30.75 µl PCR water 
0.25 µl Taq polymerase 
2) 5µI of the appropriate oligonucleotide primer was added to each tube. 
3) All components were removed from the hood, except for the reaction tubes and 
5 µl of sample cDNA added to each tube. The contents of each tube were then 
gently mixed and overlaid with three drops of mineral oil (Sigma, molecular biology 
grade) to prevent evaporation of the contents during incubation. All tubes were then 
incubated in a Hybaid thermal reactor using an appropriate programme. 
4) On completion the samples were stored at -4°C until they could be analyzed. 
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Table 2.2: Thermocycler Programme for PCR *. 
1 Cycle of 95°C for 3 min 
65°C for 1 min 
72°C for 1 min 
followed by 
33 Cycles of: 95°C for 50 sec 
65°C for 1 min 
72°C for 1 min 
followed by 
1 Cycle of : 95°C for 50 sec 
65°C for I min 
72 °C for 5 min 
(* using a Hybaid T2 thermocycler) 
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Table 2.3: Primer Sequences Used in the PCR 
IL1 a Upstream: 
No. of bases: 23 
Molecular mass (Daltons): 7032 
Sequence: 5'> GGC CAT CGC CAA TGA CTC AGA GG < 3' 
ILla Downstream: 
No. of bases: 23 
Molecular mass (Daltons): 7026 
Sequence: 5'> GCA CTG GTT GGT CTT CAT CTT GG < 3' 
ILIß Upstream: 
No. of bases: 24 
Molecular mass (Daltons): 7359 
Sequence: 5'> GAA GTA CCT GAG CTC GCC AGT GAA < 3' 
IL Iß Downstream: 
No. of bases: 24 
Molecular mass (Daltons): 7381 
Sequence: 5'> CGT GCA GTT CAG TGA TCG TAC AGG < 3' 
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Table 2.3 Cont. 
IL6 Upstream: 
No. of bases: 23 
Molecular mass (Daltons): 6841 
Sequence: 5'> CCA CAC AGA CAG CCA CTC ACC TC < 3' 
IL6 Downstream: 
No. of bases: 23 
Molecular mass (Daltons): 6866 
Sequence: 5> CTG GCT TGT TCC TCA CTA CTC TC < 3' 
TNFa Upstream: 
No. of bases: 23 
Molecular mass (Daltons): 6965 
Sequence: 5'> AGC TGC CAG GCA GGT TCT CTT CC < 3' 
TNFa Downstream: 
No. of bases: 23 
Molecular mass (Daltons): 6909 
Sequence: 5'> GGT TAT CTC TCA GCT CCA CGC CA < 3' 
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Table 2.3 Cont. 
TNFß Upstream: 
No. of bases: 24 
Molecular mass (Daltons): 7117 
Sequence: 5'> CAC CAC CTG AAC GTC TCT TCC TCC < 3' 
TNFß Downstream: 
No. of bases: 23 
Molecular mass (Daltons): 7120 
Sequence: 5' > GGA GTA GAC GAA GTA GAT GCC AC < 3' 
ß2M Upstream: 
No. of bases: 24 
Molecular mass (Daltons): 7237 
Sequence: 5' > CCT TGA GGC TAT CCA GCG TAC TCC < 3' 
ß2M Downstream: 
No. of bases: 23 
Molecular mass (Daltons): 6939 
Sequence: 5' > CCA TGA TGC TGC TTA CAT GCT TC < 3' 
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2.5: Analysis of cDNA Products. 
2.5.1: Introduction. 
The cDNA products amplified by the PCR process were analyzed by agarose gel 
electrophoresis. A Hybaid mini-gel apparatus was used. This is a horizontal slab 
gel system designed specifically for molecular biology applications. 
2.5.2: Method Employed for Electrophoresis. 
1) A 1.8% agarose gel was prepared in TBE buffer, using Seakem agarose (FMC 
Ltd. ) in a clean 250 ml glass conical flask. The agarose was melted by placing the 
flask in a domestic microwave oven on a high setting for 2 min. It was then allowed 
to cool slightly and 15µl of ethidium bromide solution added (Sigma Ltd. ). When 
hand hot, the solution was poured into a mould, with a comb (to make the wells in 
the gel) and allowed to set. 
2) As the gel was setting, the samples to be analyzed were prepared. Using 2 ml 
microfuge tubes, 3 µl of loading buffer (see appendices for details) was mixed with 
12 µl of sample cDNA for each tube. The samples were then briefly centrifuged 
in a microfuge at I0000g for lOs to collect the liquid in the bottom of the tubes. 
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2.5.2 Cont. 
3) The cast gel was placed in the gel tank, TBE buffer added to a depth to cover 
sufficiently the wells of the gel, and the comb removed. 
Each sample was then 
added to a well and the cover placed on the gel. The power supply was switched 
on and electrophoresis performed at room temperature for approximately 1 hour, at 
100 volts. 
4) Once the electrophoresis was complete, the products were visualised by using UV 
light. The gel was placed on a UV-emitting light box (on long wave setting). 
Ethidium bromide cross links DNA and causes it to fluoresce under UV light. 
Therefore, each product showed up as a fluorescent band. As each product has a 
different molecular size, each appears at a different place on the gel, due to the fact 
that short lengths of DNA can, under electrophoresis, travel faster through the gel 
than larger pieces. A molecular size marker, consisting of a mixture of DNA 
fragments of different, but known sizes, was used alongside the samples, allowing 
their sizes to be worked out. The identity of the samples was confirmed by 
comparing their sizes to the known sizes of the primer products. 
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5) A permanent record of each set of results was taken 
by photographing the 
developed gel under UV light, using a Polaroid instant black and white camera, with 
Polaroid 665 film and an exposure time of about 25s. The film also gave negatives 
from which multiple prints were made. 
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2.6: Restriction Digestion of PCR Products. 
2.6.1: Introduction. 
To verify the identity of the PCR products it was necessary to perform 
restriction digestion. The use of each oligonucelotide primer resulted in the 
formation of a unique product containing an appropriate restriction enzyme site. 
This site was present in the original sequence chosen for amplification. 
Upon reaction with the appropriate restriction enzyme, particular fragments 
of known size are produced; analysis of these confirms the identity of the PCR 
product. The table overleaf shows the expected size of each product, the restriction 
enzyme which cuts it and the expected size of each digested fragment. 
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Table 4' Expected Results of Restriction Enzyme Digestion of PCR Products. 
PCR Product Size b Res. Enzyme' 
ILIa 
ILlß 
324 EcoR I 
376 Hinf I 
IL6 313 Hinf I 
TNFa 450 Msp I 
ß2M 322 EcoR I 
Fragment Size* (bp) 
112,212 
142,234 
197,116 
54,96,300 
108,214 
* bp = base pairs. 
1 Res. Enzyme = Restriction Enzyme. 
(E. C. nos for enzymes are: EcoR I: 3.1.27.1; Hinf I: 3.1.30.1; Msp I: 3.1.30.2) 
N. B. : Information on the sequences of the PCR primers, the sizes of the products 
they give, the location of the restriction enzyme sites in the products and the sizes 
of the fragments produced by successful restriction enzyme digestion can be obtained 
from the GCG gene data bank. The following are the GCG codes for each primer: 
ILla: Pr: HUMILIAA. GB ILI3 : Pr: HUMILIBA. GB IL6: Pr: HUMIFNB2. GB 
TNFa: Pr: HUMTNFAA. GB TNFI : Pr: HUMLT. GB 02M: Pr: HUMB2M. GB 
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2.6.2: Method Used for Restriction Digestion. 
The entire procedure was performed in a laminar flow hood 
1) Two PCR products for each sample (ones which gave strong fluorescent bands on 
electrophoresis) were selected to give a volume of 100 µl per sample and combined 
in a2 ml microfuge tube. 
2) An equal volume of 50% phenol (molecular biology grade - Sigma) and 50% 
chloroform (BDH Ltd. ) was added (i. e 100 µl) to each sample and the whole lightly 
vortex mixed. 
3) The samples were centrifuged at 10000g for 3 min at 4°C. 
4) The supernatants were removed and placed in fresh 2 ml microfuge tubes, 2.5 
volumes of 100% ethanol added to each, along with 1/10 volume of 3M sodium 
acetate (pH 5.2), and the tubes placed at -20 °C for at least 15 min. 
5) The tubes were centrifuged at 10000g for 15 min at 4°C and the supernatants 
removed carefully to leave the pellets in the bottom of the tubes. These pellets were 
then washed twice in a 75% ethanol, 25% DEPC water mixture and centrifuged at 
10000g for 10s at 4°C between each wash. 
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2.6.2 Cont.: 
6) The pellets were air-dried for 5 min and resuspended in 24 µl of sterile water. 
7) The following were added to each tube: 
8 µl of the freshly extracted sample cDNA (prepared in points 1-6) 
2 µi of restriction enzyme buffer (this is supplied with the enzyme and is specific for 
it) 
I µl of the appropriate restriction enzyme 
11 µl of sterile distilled water (so the final volume is 20 µl) 
The tubes were incubated at 37°C (in a water bath) for at least lh. Following this 
the products of the digestion were visualised by electrophoresis on a 2% agarose 
(Seakem) slab gel at 100 volts for I h, followed by ethidium bromide staining and 
the result photographed. 
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2.7: Methods Used for Immuno-Staining. 
2.7.1: Introduction. 
Unlike the other techniques described, immuno-staining deals with detection of the 
protein of interest, not its mRNA. Investigation of mRNA alone does not prove that 
the protein is actually translated or secreted, so immuno-staining is important as a 
sensitive technique which directly detects the protein. The technique employs 
antibodies to the protein of interest to detect its presence in fixed or frozen tissue 
sections. Once the antibodies have reacted with the tissue, the unbound antibodies 
are washed off and the bound detected by using another suitably labelled secondary 
antibody which will bind to the primary antibody. The secondary antibody was 
fluorescent (e. g. FITC-conjugated). or Alkaline Phosphatese labelled (depending on 
the experiment) Fluorescent-conjugated antibody gives very good sensitivity, but 
alkaline phosphatase-conjugated antibody allows identification of the cells in which 
the protein has been detected and shows the morphology of the tissue. This 
technique does not give as accurate localisation of product as in-situ hybridisation 
since it will detect secreted protein in the matrix of the tissue as well as intra-cellular 
material. However, it is effective in showing that a particular tissue is producing and 
secreting the protein. 
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2.7.1 Cont.: 
For immunofluorescent investigation original samples of tissue, from which portions 
had previously been removed for mRNA analysis were used. Frozen sections were 
prepared from them on a cryostat and mounted on standard glass slides. The slides 
were stored at -20°C until they could be stained. The staining protocol was based 
on methods employed by the University Department of Orthopaedics, Western 
Infirmary, Glasgow. Primary antibody dilutions were determined in a series of 
experiments, but secondary (fluorescent) antibody dilutions were those recommended 
by the manufacturers. 
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2.7.2: Method Employed for Immuno-Staining Frozen Sections with FITC- 
Conjugated Antibody. 
1) The slides with the frozen sections were fixed in 0.5% formalin for approximately 
3 min and washed in phosphate buffered saline for 5 min. 
2) The slides were then reacted with the primary antibody (see Table 2.2 for details) 
at 4°C overnight and rinsed 3 tunes in PBS. The antibody dilutant used to make up 
the dilutions of primary antibody (and secondary antibody) was PBS antibody 
dilutant (87m1 of 0.01 M PBS and 3ml of 30 % bovine serum albumin) 
3) The secondary antibody was then applied (this was FITC-conjugated) for 30 min 
in the dark, followed by washing 3 times in PBS (5 min per wash) and mounted in 
diazobicyclo (2,2,2) octane mountant (D. A. B. C. O. ). They were viewed immediately 
using a microscope with UV illumination. 
The table overleaf details the antibodies used, and their dilutions: 
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Table 2.5- Antibodies Used for Immunofluorescent Staining of Frozen Sections and 
their Dilutions. 
Primary Antibody Antibody Dilution Secondary Antibody 
Antibody Dilution 
IL Ia (Sheep) 1: 4000 FITC-Conjugated 1: 128 
Anti-Sheep 
(Sigma) 
IL6 (Goat) 1: 4000 FITC-Conjugated 1: 64 
Anti-Goat 
(Sigma) 
CD8 (Mouse) 1: 4000 FITC-Conjugated 1: 80 
Anti-Mouse* 
CD14 (Mouse) 1: 4000 FITC-Conjugated 1: 80 
Anti-Mouse 
CD21 (Mouse) 1: 4000 FITC-Conjugated 1: 80 
Anti-Mouse 
*CD marker antibodies supplied by Scottish Antibody Production Unit. 
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2.7.3: Protocol Used for Immuno-Histoloszical Staining Using Alkaline Phosphatase 
Conjugated Secondary Antibodies Detected by the Fast Red" Method on Paraffin- 
Embedded Sections . 
1)Tissue was collected as soon as possible after surgery and placed in 0.5% formalin 
for 24h. 
2) Following this it was placed in 70% ethanol for 24h, then 90% ethanol for 3h, 
then 100% ethanol for 24h to ensure that the tissue was fully dehydrated. 
3) The tissue was placed in Xylene ("Histoclear") for a minimum of 4h or until it 
was microscopically clear. 
4) The tissue was placed in a bath of molten paraffin for 24h, and the embedded in 
paraffin. 
5) The embedded tissue was sectioned on a microtome, and the sections mounted on 
glass slides coated with 3-amino-propyl-tri-ethoxy silane (APES) 
108 
2.7.3 Cont. 
6) The mounted sections were washed in tris-buffered saline (TBS), and subjected 
to digestion by a 0.5% trypsin solution (0.1 g trypsin, activity 8980 U/mg, E. C. no. 
3.4.21.4; 0.1 g calcium chloride; dissolved in 100ml of TBS at 37°C) at 3 7°C for 15 
min. 
7) The slides were then washed in TBS and the primary antibody added at the 
appropriate dilution (see Table 2.6). One slide for each sample was used as a 
negative control and received only antibody dilutant. The antibody dilutant was TBS 
antibody dilutant (made as for PBS antibody dilutant on p105 but substituting 87m1 
of 0.85% TBS for the PBS). The slides were then left at 4°C for 24h and rinsed 3 
times in TBS. 
8) The appropriate secondary antibody was then applied to each slide and left to 
react for lh in the dark. The slides were then washed 3 times in TBS. 
9) Detection of the secondary antibody was carried out using a Sigma Fast Red TM 
detection kit in accordance with the manufacturer's instructions, summarised as 
follows: 
a) Tablets of O. lml tris buffer (supplied) were dissolved in lml of distilled 
water each (one per slide). 
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2.7.3 Cont. 
b) To these were added 1 tablet each of Fast Red TRINapthol AS-MX 
solution, and the tablets dissolved. The Fast Red / buffer solution was 
then applied to the slides immediately, and the slides monitored under a 
microscope at x10 magnification until a pink or red colour was observed. 
The staining reaction was then terminated by placing the slides in tap water. 
10) The developed slides were then counter-stained with haematoxylin for 12s, 
mounted in gelatin and stored. Where required, they were photographed using 
Kodak EPT-160T colour slide film. 
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TABLE 2.6: Antibodies Used for Immuno-Histological Staining Using Alkaline 
Phosnhatase - Conjugated Secondary Antibodies and Their Dilutions. 
Primary Antibody Antibody Dilution Secondary Antibody Dilution 
Antibody 
IL Ia (Sheep) 1: 60 Alkaline 1: 125 
Phosphatase - 
Conjugated Anti - 
Sheep 
IL6 (Goat) 1: 60 Alkaline 1: 64 
Phosphatase - 
Conjugated Anti - 
Goat 
CD68 (Clone KP-1) 1: 75 Alkaline 1: 50 
Macrophage Marker Phosphatase - 
(Mouse)* Conjugated Anti - 
Mouse 
*Tissue being stained with this marker had to be visually examined for mast cells 
(distiguishable from macrophges by their cell morphology) as these also display the 
CD68 marker. 
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2.8: Method Employed for Haematoxylin and Eosin Staining. 
1) The slides were stained with I drop of haematoxylin (obtained from the hospital 
Pathology Department) for 5 min and rinsed carefully with tap water. 
2) The slides were then stained with I drop of eosin (obtained from the hospital 
Pathology Department) for 5 min and rinsed carefully in tap water. 
3) The finished slides were then mounted in gelatin and kept safe. 
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2.9: Tissue Culture Methods Employed. 
2.9.1: Maintenance of Adherent Cell Lines. 
The adherent cell lines (MCF-7 and T-24) were routinely grown in 75 cm2 
polystyrene culture flasks (Bibby) in RPMI 1640 culture medium (GIBCO Ltd. ) with 
the following supplementations: 10% foetal calf serum, 1% penicillin/ streptomycin, 
1% glutamine 
(all GIBCO Ltd. ), until confluent. The medium used for MCF-7 cells was phenol 
red free. 
When confluent, the cells were removed by trypsinisation. 5ml of trypsin 
(0.25% crude) was added to each flask, and the flasks incubated in an ordinary 
incubator at 37°C for approximately 10 min until the cells were observed floating 
free. The Trypsin was then removed by washing the cells in l0mi of culture 
medium, followed by centrifugation at 5000g for 10 min at room temperature. The 
resulting pellet of cells was drained and resuspended in Iml of culture medium. The 
cells were counted in a haemocytometer using trypan blue dye to measure their 
viability (cells taking up the dye considered as dead) and reseeded at an appropriate 
concentration in fresh flasks with fresh medium. Incubation conditions were 37°C, 
5%C02,95% air. 
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2.9.2: Maintenance of Non-adherent Cell Lines. 
Culture conditions were similar for the B9 cell line although it was non-adherent. 
The medium was as described in 2.8.1, except for the addition of ß-mercaptoethanol 
to a final concentration of 5x10'5 M. This cell line also required supplementation 
with crude IL 6 (hybridoma growth factor, Janssen) each time the cells were 
subcultured, at a final concentration of approximately 0.1%, 
The B9 cells could not be grown above a concentration of 5x105 cells per ml 
otherwise they were found to lose their sensitivity to IL 6. They were always 
subcultured before reaching this concentration, usually being diluted by a factor of 
1/10. Cell transfer or subculture did not require the use of trypsin, as the cells float 
free in the medium. 
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2.10: Methods Employed in Growth Studies on Cells. 
2.10.1: Introduction. 
The effects of IL6 on growth of cells was studied in two separate experiments. 
These were similar in design, but differed from one another in the type of IL6 used 
(crude natural, or recombinant), and in the way that the cell proliferation was 
measured. 
2.10.2: Method Employed for Cell Growth Studies Using Crude Hybridoma Growth 
Factor. 
The first method was designed to study the effects of IL6 on the MCF-7 cell 
line, and used cells cultured in 24 well flat-bottomed microtitre plates. 
1) The cells were distributed into the wells on the plate. In all, 8 wells were used, 
one row of 4 as an untreated control, and one row of 4 as the treated populations. 
Approximately 3000 cells were added to each well in 1 ml of culture medium. The 
wells in the control set also received 100 µl of PBS, while those in the treated set 
received 100 µl of hybridoma growth factor of initial activity 400 U/ml, so that the 
final concentration in each well was approximately 36 U/ml. 
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2.10.2 Cont.: 
1 Cont. ) The medium used was RPMI 1640 with the usual supplements (see 2.9.1 
p 113) and no phenol red as this is weakly oestrogenic and might 
interfere with the 
experiment. Following this the plate was placed in an incubator at standard 
conditions (2.9.1. p113). 
2) The cells in one well for the treated population, and one well for the control 
population were harvested by trypsinisation each day, giving an experiment lasting 
4 days. The cell concentration in each well was determined using a haemocytometer. 
3) At the end of 4 days, graphs of cell number versus time were plotted for the 
control and treated populations and these graphs compared to determine whether IL6 
caused any effect on growth 
2.10.3: Method Employed for Cell Growth Studies Using Human Recombinant IL6. 
M. T. T. dye absorbance was employed in the second study to determine the cell 
population. It used only 2 incubation periods, 48 and 72 h, and recombinant IL6 at 
different concentrations. 
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2.10.3 Cont.: 
1) Two 96 well flat-bottomed microtitre plates. were prepared as shown in table 2.6 
overleaf. Serial IL6 dilutions were prepared 
down the plate and cells of each type 
were added to the wells (see table 2.7 for details). All cell types were added to the 
wells to give the same initial concentration, 5x104 cells/ml. This is a higher initial 
concentration than was used in 2.10.2 and was used to enable the detection method 
to give measurable results. 
The detection method is based on dye absorbance, the greater the number of 
cells, the greater the final dye absorbance. However, the initial cell concentration 
has to be large enough to ensure that the final cell concentrations will be sufficient 
to give easily measurable absorbance values. 
2) At the conclusion of the incubation periods (either 48 or 72 h) cell concentrations 
were determined using the M. T. T. dye method. I Ogl of M. T. T. dye (5mg/ml, Sigma) 
was added to each well on the plate. The plate was then incubated for 4h at 
standard conditions (2.9.1 p113). 50µ1 of Triton-x detergent (10%, made up in 
0.05M HCl) was added to each well to solubilise the dye precipitate. This process 
required the plate to be returned to the incubator for a further 12 h. 
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2.10.3 Cont.: 
3) The absorbances of each well were then measured in a plate reader at 540nm. 
4) Graphs were drawn of concentration of IL6 versus absorbance (growth) for each 
cell line for each incubation period and the effects of IL6 observed from the graphs. 
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Chapter 3: Results 
31. Validation of the Method and Primers used in the PCR Experiments. 
As has been explained on p89, the PCR technique can produce artefacts and 
care has to be taken to avoid contamination with extraneous DNA which will lead 
to false positive results. However, care also has to be taken to avoid the generation 
of false negative results. These can occur if the primers for the PCR reaction are 
incorrect, or if the conditions of the PCR reaction are not at their optimum. To 
ensure this, a set of experiments was carried out to ensure that the primers were 
performing correctly and that the method was using optimum conditions. It should 
be pointed out that all the PCR experiments were repeated at least twice to ensure 
reproducibility of results. All the results reported in this section and those in 
sections 3.2 and 3.3 were reproducible. 
Stimulated macrophages produce IL 1 a, IL 1 ß, IL6, TNFc , and 
TNFB. Almost 
all nucleated cells produce ß2 microglobulin (ß2M) including macrophages so it 
should be detected as well. Macrophages were extracted from blood and stimulated 
with Lipopolysaccharide (LPS). After culture in RPMI medium for 24h at standard 
conditions (p113), mRNA was harvested as described (p77 ), reverse transcribed 
(p83), and PCR performed (p90). Results were obtained by agarose gel 
electrophoresis followed by ethidium bromide staining (p97). 
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Figure 3.1 shows the results obtained. Lanes I and 8 show the molecular size 
markers. In lane 2 there is a broad faint band of molecular size approximately 
320. 
This corresponds to the expected mass of the IL Ia product (see table 2.4 p101). In 
the same lane is another faint band which is above the last of the molecular size 
markers and is likely to be primer dimer (due to it being so small). Lane 2 used the 
primers for IL1 a and the band observed was near to the expected size of the IL 1a 
product (324 bp) so a positive result can be concluded for IL 1a expression. Lane 
3 (using material prepared with primers for IL I ß) shows a similar result to lane 2, 
2 bands, one of molecular size approximately 350 bp and one of very small size. 
The small product is probably primer dimer and the other product is around the 
expected size for IL 1ß (376 bp). This would indicate a positive result for IL 1 ß. 
Lane 4 (using material prepared with primers for IL6) shows 1 strong band of around 
310 bp, which is close to the expected size of the IL6 product (313 bp), indicating 
a positive result for IL6. Lane 5 (using material prepared with primers for TNFa) 
shows a band of molecular size approximately 420bp, which is close to the expected 
size of the TNFa product, indicating a positive result for TNFa. Lane 6 shows 2 
bands, the smaller of which is probably primer dimer, and the other is about 320 bp. 
This is close to the expected size of the TNFß product (344 bp), indicating a positive 
result for TNFß. 
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Lane 7 shows one very strong band of molecular size approximately 
320 bp, which 
is near the expected mass of the 
ß2M product. (322 bp), indicating a positive result 
for ß2M. However, there are other bands visible in this lane, all of smaller sizes 
than the ß2M product, giving a laddering effect. They are probably products of 
partial PCR caused by the annealing temperature for the primer being too high. 
A positive result for every primer set was obtained indicating that the primers 
were suitable and the method satisfactory. However, it was necessary to check that 
the products observed were appropriate to each primer set and not false positive 
results. Restriction digestion of each macrophage primer product was carried out as 
described on p100. Following this, electrophoresis (as described on p97) was 
performed on both restriction digested and undigested primer products. The results 
obtained are shown in figure 3.2. Table 2.4 (p 101) gives the mol sizes of each intact 
product (obtained from GCG gene bank) and the number of fragments and fragment 
mass for each digested product. 
Lane I shows the molecular size markers, as 8 distinct bands, of sizes (bottom to 
top) 1353 bp, 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 194 bp. 
Lane 2 (using material prepared with the IL Ia primers, undigested) shows a band 
near 324bp, the expected size of the intact ILla product. 
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Lane 3 (using the same material as that in lane 1, but 
digested with EcoR I) shows 
a bright band of around 212 bp, and a slightly 
fainter band at around 112 bp, the 
expected sizes of the fragments for digested ILIa product. 
Lane 4 (using material 
prepared with the ILIß primers, undigested) shows 1 bright 
band around 376 bp, the 
expected size of the intact IL Iß product. Lane 5 (using the same material as lane 
4, but digested with Hinf I) shows I band around 234 bp and another around 142 bp, 
the expected sizes of the fragments for digested ILIß product. There is also a band 
at the top of the lane which is probably primer dimer. Lane 6 (using material 
prepared with the TNFa primers, undigested) shows 1 band of around 450 bp, the 
expected size for intact TNFa product. Lane 7 (using the same material as lane 6, 
but digested with MSP I) shows a bright band around 300 bp, and another fainter 
band of around 94 bp, corresponding to the expected masses of 2 of the fragments 
of digested TNFa product. The expected third fragment of 54 bp is not present. 
Lane 8 (using material prepared with the TNFß primers), shows a faint band of 400 
bp, a bright band of 344 bp, and a faint band of 95 bp. The band of 344 bp is 
approximately the size of the expected product, the other 2 bands are artefacts. Lane 
9 (using the same material as 8, but digested with MSP I) shows a bright band of 
236 bp, another band of 95 bp, and a faint band at the top of the lane. These 
correspond to the expected fragment sizes of the digested TNFß product. 
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Lane 10 (using material prepared with the IL6 primers shows I bright band of around 
313 bp, the expected size of the IL6 product. Lane 11 (using the same material as 10, 
but digested with Hinf I) shows 2 bright bands of around 197 and 116 bp, the expected 
fragment sizes of the digested IL6 product. Lane 12 (using material prepared with the 
ß2M primers) shows 1 band around 322 bp, the expected size of the ß2M product. 
Lane 13 (using the same material as 12, but digested with EcoR I) shows I band of 
around 214 bp, the expected size of one of the fragments of the digested ß2M product. 
There should also be a fragment of 108 bp, but this cannot be observed. 
The results confirmed that the primers and method used could successfully 
detect cDNA for all of the cytokines of interest in experiments in which macrophages 
were the source of mRNA. 
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Molecular 
Size Markers (bp). 
Lanes 
Figure 3.1: Photograph of PCR result using intact PCR products prepared (p90) 
from cDNA reverse transcribed from mRNA extracted from peripheral blood 
macrophages cultured for 24h and stimulated with lipopolysaccaride (culture 
conditions p113). Photograph shows PCR products on an agarose slab gel, on 
which electrophoresis was performed as on p97, and staining carried out with 
ethidium bromide. Film used for photography was polaroid 665 and the exposure 
time for the photograph was 25s. A detailed description is given overleaf. 
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Description of Figure 3.1: Lanes 1 and 8: Samples are molecular size markers. 8 
bands observed corresponding to the markers of masses 1353 base pairs (bp), 1078 
bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 194 bp. 
Lane 2: Sample probed for IL1 a. 1 band observed approx. 324 bp, expected size 
for IL1 a PCR product, band considered positive result for IL1 a. 
Lane 3: Sample probed for IL 1 ß. I band observed approx. 376 bp, expected size 
for IL 1ß PCR product, band considered positive result for IL I ß. 
Lane 4: Sample probed for IL6.1 band observed approx. 313 bp, expected size for 
IL6 PCR product, band considered positive result for IL6. 
Lane 5: Sample probed for TNFa. I band observed approx. 450 bp, expected size 
for TNFa PCR product, band considered positive result for TNFa. 
Lane 6: Sample probed for TNFß. 1 band observed approx. 344 bp, expected size 
for TNFß PCR product, band considered positive result for TNFß. 
Lane 7: Sample probed for ß2M. 1 band observed approx. 322 bp, expected mass 
for ß2M PCR product, band considered positive result for ß2M. 
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Figure 3.2: Photograph of PCR result using intact PCR products and restriction 
enzyme digested PCR products (see p100 for restriction digestion method) prepared 
from cDNA reverse transcribed from mRNA extracted from peripheral blood 
macrophages cultured for 24 h and stimulated with lipopolysaccaride (culture 
conditions p 113). Photograph shows PCR products on an agarose slab gel, on which 
electrophoresis was performed as on p97, and staining carried out with ethidium 
bromide. Film used for photography was polaroid 665 and the exposure time for the 
photograph was 25s. A detailed description is given overleaf. 
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Description of Figure 3.2: Lanes 1: Samples are molecular size markers. 8 
bands observed corresponding to the markers. of masses 1353 
base pairs (bp), 
1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 194 bp. 
Lane 2: Intact sample probed for Ma. 1 band of correct sizes (324 bp) for 
IL1 a product so result positive for IL1 a. 
Lane 3: IL1 a sample digested with EcoR I giving 2 fragments of approx 112 and 
212 bp, correct sizes of fragments, therefore product confirmed as IL Ia product. 
Lane 4: Intact sample probed for ILIß. 1 band of correct size (376 bp) for ILlß 
product so result positive for IL 1 ß. 
Lane 5: ILlß sample digested with Hinf I giving 2 fragments of approx 142 and 
234 bp, correct sizes of fragments, therefore product confirmed as ILlß product. 
Lane 6: Intact sample probed for TNFa. I band of correct size (450 bp) for 
TNFa product so result positive for TNFa. 
Lane 7: TNFa sample digested with Msp I giving 3 fragments of approx 54 bp, 
96 bp, and 300 bp, correct sizes of fragments, therefore product confirmed as 
TNFa product. 
Lane 8: Intact sample probed for TNFß. 1 band of correct size (344 bp) for 
TNFß product so result positive for TNFß. 
Lane 9: TNFß sample digested with Msp I giving 3 fragments of approx 13 bp, 
95 bp, and 236 bp, correct sizes of fragments, therefore product confirmed as 
TNFß product. 
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Description of Figure 3.2 Cont.: 
Lane 10: Intact sample probed for IL6. I band of correct size (313 bp) for IL6 
product so result positive for IL6. 
Lane 11: IL6 sample digested with Hinf I giving 2 fragments of approx 116 bp, 
and 197 bp, correct size of fragments, therefore product confirmed as IL6 product. 
Lane 12: Intact sample probed for ß2M. 1 band of correct size (322 bp) for 
ß2M product so result positive for ß2M. 
Lane 13: ß2M sample digested with EcoR I giving 2 fragments of approx 108 bp, 
and 214 bp, correct sizes of fragments, therefore product confirmed as ß2M 
product. 
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3.2: Investigation of the Patterns of Cytokine Production in Tumour Cell Lines. 
A study by Tabibzadeh et al (1989) indicated that the bladder cell line T-24, 
and the breast cell line MCF-7 produced IL6. A series of experiments were carried 
out to confirm that the primers and PCR method could detect this. Production of 
ILl a, IL l ß, TNFa, TNFß, and ß2M (as a positive control) were also to be examined. 
For these experiments, cells of the appropriate lines were cultured for approximately 
72 h, until confluent. mRNA was extracted (p77), reverse transcribed, (p83), and 
PCR performed (p90). The results were analysed by agarose gel electrophoresis 
(p97) and are shown in figure 3.3. Lanes I and 7 show 10 bands corresponding to 
the molecular size markers of sizes (bottom to top) 1353 bp, 1078 bp, 872 bp, 603 
bp, 310 bp, 281 bp, 234 bp, 194 bp, 118 bp. Lane 2( material from T-24 cell line 
prepared with the IL1 a primers) shows a band of around 324 bp, the expected size 
of the IL 1a product. Lane 3 (material from T-24 cell line prepared with the IL 1ß 
primers) shows no bands, indicating a negative result. Lane 4 (material from T-24 
cell line prepared with the IL6 primers) shows a band around 313 bp, the expected 
size of the IL6 product. Lane 5 (material from T-24 cell line prepared with the 
TNFa primers) shows no bands indicating a negative result. Lane 6 (material from 
T-24 cell line prepared with the TNFß primers) shows no bands, indicating a 
negative result. 
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Lane 8 (material from MCF-7 cell line prepared with the ILl a primers) shows a 
band of around 324 bp, the expected size of, the IL 1a product. Lane 9 (material 
from MCF-7 cell line prepared with the ILlß primers) shows a band of around 376 
bp, the expected size of the IL 1ß product. Lane 10 (material from MCF-7 cell line 
prepared with the IL6 primers) shows a band around 313 bp, the expected size of the 
IL6 product (sizing is approximate and in a strong band like the one here, there is 
a resolution limit of about 20bp and this is why the product looks larger than it is). 
Lane 11 (material from MCF-7 cell line prepared with the TNFa primers) shows no 
bands, indicating a negative result. Lane 12 (material from MCF-7 cell line prepared 
with the TNFß primers) shows no bands, indicating a negative result. 
The results of the experiments showed that the T-24 cell line constitutively 
produced IL 1a and IL6, and the MCF-7 cell line constitutively produced IL l a, IL 1 ß, 
and IL6. 
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Lanes 
Figure 3.3: Photograph of the PCR result obtained using PCR products prepared 
(p90) from cDNA reverse transcribed from mRNA extracted from the cell line T-24 
(bladder) and the cell line MCF-7 (breast), cultured to confluence as described on 
p112. Photograph shows PCR products on an agarose slab gel on which 
electrophoresis was performed as on p97, staining was carried out with ethidium 
bromide. Film used for photography was polaroid 665 and the exposure time for the 
photograph was 25s. A detailed description is given overleaf. 
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Description of Figure 3.3: Lanes l and 7 molecular size markers. 9 bands observed 
of sizes: 1353 base pairs (bp), 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 
194 bp, 118 bp. 
Lane 2: Sample from T-24 probed for ILla. 1 band observed approx. 324 bp, 
expected size for ILla PCR product, band considered positive result for ILla. 
Lane 3: Sample from T-24 probed for ILlß. No bands observed, considered 
negative result for 1113 
Lane 4: Sample from T-24 probed for IL6. I band observed approx. 313 bp, 
expected size for IL6 PCR product, band considered positive result for IL6. 
Lane 5: Sample from T-24 probed for TNFa. No band observed, considered 
negative result for TNFa. 
Lane 6: Sample from T-24 probed for TNFß. No band observed, considered 
negative result for TNFß. 
Lane 8: Sample from MCF-7 probed for ILIa. I band observed approx. 324 bp, 
expected size for IL Ia PCR product, band considered positive result for IL 1 a. 
Lane 9: Sample from MCF-7 probed for ILIß. 1 band observed approx. 376 bp, 
expected size for ILIß PCR product, band considered positive result for IL1ß. 
Lane 10: Sample from MCF-7 probed for IL6.1 band observed approx. 313 bp, 
expected size for IL6 PCR product, band considered positive result for IL6. 
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Description of Figure 3.3 Cont.: 
Lane 11: Sample from MCF-7 probed for TNFa. No band observed, considered 
negative result for TNFa. 
Lane 12: Sample from MCF-7 probed for TNFß. No band observed, considered 
negative result for TNFß. 
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3.3: Investigation of Cytokine Production in Tumours. 
Tumour samples were collected as soon as possible after surgery, snap frozen 
in liquid nitrogen and the mRNA extracted as detailed, reverse transcribed (p77-83 
respectively), PCR was performed to analyse the resulting cDNA (p90), and the 
result analysed by agarose gel electrophoresis (p97). In this way a cytokine 
production profile could be built up for each tumour sample. The results of the 
profiling were collated for each tumour type and represented graphically. 
Figure 3.4 shows the collated results for the breast tumour samples. No 
samples had detectable cDNA for IL 1a or IL 1 ß, 5 out of 9 samples had detectable 
cDNA for IL6,2 out of 9 samples had detectable cDNA for TNFa, 1 out of 9 
samples had detectable cDNA for TNFB, and all 9 samples had detectable cDNA for 
ß2M. 
Figure 3.5 shows a sample result for one of the breast tumours. Lanes 1 and 
9 show 9 bands corresponding to the molecular size markers of sizes (top to bottom) 
1353 bp, 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 194 bp, 118 bp. Lanes 
2,3, and 6 show no bands indicating a negative result for ILla, ILIß, and TNFß. 
Lane 4 (using material prepared with the IL6 primers) shows a bright band at 313 
bp, the expected size for the IL6 product. 
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Lane 5 (using material prepared with the TNFa primers) shows a band around 450 
bp, the expected size of the TNFa product. Lane 7 (using material prepared with the 
ß2M primers) shows 1 bright band around 322 bp, the expected size of the ß2M 
product. Lane 8 (using material prepared with no cDNA, only ß2M primers as a 
negative control) shows no bands, as expected. 
Figure 3.6 shows the collated results for the bladder tumour samples. 4 out 
of 13 samples gave detectable cDNA for IL l a, none gave cDNA for IL l ß, 7 out of 
13 gave detectable cDNA for IL6, I out of 13 gave detectable cDNA for TNFa, I 
out of 13 gave detectable cDNA for TNFß, and all 13 gave detectable cDNA for 
ß2M. 
Figure 3.7 shows a sample result for one of the bladder tumours. Lanes 1 and 
8 show the molecular size markers, observed as 9 bands of sizes (bottom to top) 
1353 bp, 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 234 bp, 194 bp, 118 bp. Lane 
2 (using material prepared with the ß2M primers) shows a band of approx. 322 bp, 
the expected size of the ß2M product. Lanes 3,4,6, and 7 show no bands, 
indicating a negative result for TNFa, TNFß, ILIa and ILlß respectively. Lane 5 
(using material prepared with the IL6 primers) shows I band of approx. 313 bp, the 
expected size for the IL6 product. 
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Figure 3.8 shows the collated results for the lung tumour samples. All the tumours 
were malignant but were not all of the same type (see 3.6). No tumours gave 
detectable IL 1a cDNA, no tumours gave detectable IL 10 cDNA, and 6 tumours gave 
detectable TNFß cDNA. 
Figure 3.9 shows the collated results for the non-malignant lung samples. All of 
these came from the same patients as the tumours, but from the regions as far from the 
area of malignancy as possible. No samples gave detectable IL 1a or IL 1ß cDNA, 3 
out of 4 samples gave detectable IL6 cDNA, no samples gave detectable TNFa or 
TNFI cDNA, and 4 samples gave detectable 02M cDNA. 
Figure 3.10 shows a sample result for the lung tumours with the result for the 
corresponding sampe of non-malignant lung. Lanes 1,5, and 11 are the molecular size 
markers seen as 8 bands of sizes 1353 
_ 
194 bp. Lane 4 (using tumour material 
prepared with the IL6 primers) shows 1 band around 313 bp, the expected size of the 
IL6 product. 
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Lane 8 (using non-malignant lung material prepared with the IL6 primers) shows I 
band around 313 bp, the expected size of the IL6 product. Lane 9 (using non- 
malignant lung material prepared with the TNFa primers) shows I band of about 
300bp. This is too small to be TNFa as its expected size is 450 bp. The band is 
some sort of contaminant and illustrates the danger of misinterpreting false positive 
results in PCR. 
Lanes 2 and 3 showed no bands, indicating that no cDNA was detected for 
ILla and ILIß in the lung tumour. No bands were also observed in lanes 6,7, and 
10, indicating that no cDNA was detected for IL 1 a, IL 1 ß, and TNFI3 in the non- 
malignant lung. 
Only 2 of the 4 ovarian tumours sampled had intact mRNA. One gave a 
positive result for ILla, ILlß, and ß2M, and the other a positive result for TNFa, 
and ß2M only. 3 normal ovaries were also profiled. All 3 were positive for ß2M, 
and 2 out of the 3 were positive for IL1 a. The results were too few to put on a 
graph. Figure 3.11 shows the result obtained for one of the tumours, and one of the 
normal ovaries (not from the same patient). Lanes I and 14 show the molecular size 
markers seen as 8 bands of sizes (bottom to top) 1353 bp, 1078 bp, 872 bp, 
603 bp, 310 bp, 281 bp, 234 bp, 194 bp. 
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Lane 2 (using ovarian tumour material prepared with the IL1 a primers) shows 
1 faint 
band around 324 bp, the expected size of the IL Ia product. Lane 3 (using ovarian 
tumour material prepared with the ILlß primers) shows 1 strong band around 376 
bp, the expected size of the ILlß product. Lane 7 (using ovarian tumour material 
prepared with the ß2M primers) shows I faint band around 322 bp, the expected size 
of the ß2M product. Lanes 4,5, and 6, show no bands indicating negative results 
for IL6, TNFa, and TNFß in the ovarian tumour. 
In lanes 8-13, the results from a normal ovary (not from the same patient), 
lanes 8-12 show no bands indicating negative results for ILIa, ILlß, IL6, TNFa, and 
TNFß, but lane 13 (using normal ovarian material prepared with the ß2M primers) 
shows 1 faint band around 322 bp, the expected size of the ß2M product. 
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Figure 3.4: Breast Tumour Results from PCR Experiments 
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Figure 3.4: Collated results of cytokine profiles for the breast tumour samples 
prepared by PCR analysis of cDNA prepared from extracted tumour mRNA ( see 
p77-90 for methods). 20 samples were collected and profiled out of which 9 gave 
a positive result for ß2M. All samples which have undergone PCR successfully give 
a positive result for ß2M. Therefore only the 9 samples positive for ß2M gave valid 
results. The graph shows the number of tumour samples giving a positive result for 
each cytokine probed for. 
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Molecular Size 
Markers (bp). 
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Figure 3.5: Photograph of the PCR result obtained from a ductal cell breast 
carcinoma. Tissue was collected and snap frozen immediately after surgery, mRNA 
extracted (p77), reverse transcribed (p83), and PCR performed (p90). Photograph 
shows PCR products on an agarose slab gel on which electrophoresis was performed 
(p97), staining following electrophoresis was carried out with ethidium bromide. 
Film used for photography was polaroid 665 and the exposure time for the 
photograph was 25s. 
A detailed description is given overleaf. 
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Description of Figure 3.5: Lanes I and 9 are molecular size markers, observed as 
9 bands of sizes: 1353 base pairs (bp), 1078 bp, 872 bp, 603 
bp, 310 bp, 281 bp, 
234 bp, 194 bp, 118 bp. 
Lane 2: Sample from breast tumour probed for IL1 a. No bands observed, 
considered negative result for ILl a. 
Lane 3: Sample from breast tumour probed for IL 1 ß. No bands observed, 
considered negative result for IL l ß. 
Lane 4: Sample from breast tumour probed for IL6. I band observed approx. 313 
bp, expected size for IL6 PCR product, band considered positive result for IL6. 
Lane 5: Sample from breast tumour probed for TNFa. 1 band observed approx. 450 
bp, expected size for TNFa PCR product, band considered positive result for TNFa. 
Lane 6: Sample from breast tumour probed for TNFß. No bands observed, 
considered negative result for TNFß. 
Lane 7: Sample from Breast tumour probed for ß2M. 1 band observed approx. 322 
bp, expected size for ß2M PCR product, band considered positive result for ß2M. 
Lane 8: No sample, only PCR reaction mix and primers, as negative control. Lane 
blank, therefore no contamination by extraneous DNA. 
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Figure 3.6: Bladder Tumour Results From PCR Experiments 
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Figure 3.6: Collated results of cytokine profiles for the bladder tumour samples 
prepared by PCR analysis of cDNA prepared 
from extracted tumour mRNA (see 
p77-90 for methods). 21 samples were collected and profiled out of which 13 gave 
a positive result for ß2M. All samples which have undergone PCR successfully give 
a positive result for ß2M. Therefore only the 13 samples positive for ß2M gave 
valid results. The graph shows the number of tumour samples giving a positive 
result for each cytokine probed for. 
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Figure IT Photograph of the PCR result obtained from a transitional cell bladder 
carcinoma. Tissue was collected and snap frozen immediately after surgery, mRNA 
extracted (p77), reverse transcribed (p83), and PCR performed (p90). Photograph 
shows PCR products on an agarose slab gel on which electrophoresis was performed 
(p97), staining following electrophoresis was carried out with ethidium bromide. 
Film used for photography was polaroid 665 and the exposure time for the 
photograph was 25s. 
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pescription of Figure IT Lanes 1 and 8 are molecular size markers, observed as y \IJV 
9 bands of sizes: 1353 base pairs (bp), 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 
234 bp, 194 bp, 118 bp. 
Lane 2: Sample from bladder tumour probed for ß2M. 1 band observed approx. 
322 bp, expected size for ß2M PCR product, band considered positive result for 
ß2M. 
Lane 3: Sample from bladder tumour probed for TNFa. No bands observed, 
considered negative result for TNFa. 
Lane 4: Sample from bladder tumour probed for TNFß. No bands observed, 
considered negative result for TNFß. 
Lane 5: Sample from bladder tumour probed for IL6.1 band observed approx. 313 
bp, expected size for IL6 PCR product, band considered positive result for IL6. 
Lane 6: Sample from bladder tumour probed for IL 1 a. No bands observed, 
considered negative result for IL1 a. 
Lane 7: Sample from bladder tumour probed for ILIß. No bands observed, 
considered negative result for IL I B. 
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Figure 3.8: Lung Tumour Results from PCR Experiments. 
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Fib 3.8: Collated results of cytokine profiles for the lung tumour samples 
prepared by PCR analysis of cDNA prepared 
from extracted tumour mRNA ( see 
p77-90 for methods). Ii samples were collected and profiled out of which 6 gave 
a positive result for ß2M. All samples which have undergone PCR successfully give 
a positive result for ß2M. Therefore only the 6 samples positive for ß2M gave valid 
results. The graph shows the number of tumour samples giving a positive result for 
each cytokine probed for. 
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Figure 3.9: Non-malignant Lung Results from PCR Experiments 
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Figure 3.9: Collated results of cytokine profiles for the non-malignant lung samples 
prepared by PCR analysis of cDNA prepared from extracted tumour mRNA ( see 
p77-90 for methods). 13 samples were collected and profiled out of which 4 gave 
a positive result for ß2M. All samples which have undergone PCR successfully give 
a positive result for ß2M. Therefore only the 4 samples positive for ß2M gave valid 
results. The graph shows the number of tumour samples giving a positive result for 
each cytokine probed for. 
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Figure 3.10: Photograph of the PCR result obtained from a lung tumour and from 
a non-malignant lung (not from the same patient). Tissue was collected and snap 
frozen immediately after surgery, mRNA extracted (p77), reverse transcribed (p83), 
and PCR performed (p90). Photograph shows PCR products on an agarose slab gel 
on which electrophoresis was performed (p97), staining following electrophoresis was 
carried out with ethidium bromide. Film used for photography was polaroid 665 and 
the exposure time for the photograph was 25s. A detailed description is given 
overleaf. 
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Description of FigLure 3.10: Lanes 1,5, and 10 are molecular size markers, observed 
as 8 bands of sizes: 1353 base pairs (bp), 1078 bp, 872 bp, 603 bp, 310 bp, 281 bp, 
234 bp, 194 bp. 
Lane 2: Sample from lung tumour probed for IL 1 a. No bands observed, considered 
negative result for ILla. 
Lane 3: Sample from lung tumour probed for IL 1 ß. No bands observed, considered 
negative result for IL I B. 
Lane 4: Sample from lung tumour probed for IL6. I band observed approx. 313 bp, 
expected mass for IL6 PCR product, band considered positive result for IL6. 
Lane 6: Sample from non-malignant lung probed for IL 1 a. No bands observed, 
considered negative result for IL1 a. 
Lane 7: Sample from non-malignant lung probed for IL 1 ß. No bands observed, 
considered negative result for IL 1 ß. 
Lane 8: Sample from non-malignant lung probed for IL6. I band observed approx. 
313 bp, expected size for IL6 PCR product, band considered positive result for IL6. 
Lane 9: Sample from non-malignant lung probed for TNFa. 1 band observed 
approx. 300 bp, not expected size for TNFa PCR product (approx. 450bp), band 
considered to be artefact and so counted as negative result for TNFa. 
Lane 10: Sample from lung probed for TNFß. No bands observed, considered 
negative result for TNFß. 
150 
Molecular Size 
Markers (bp). 
194--- 
234, 
--__ 
281---- 
310---. 
603-, 
872 --ý` 
1078----: _ 
1353 
ýýý ý14 
Lanes 
Figure 3.11: Photograph of the PCR result obtained from a papillary 
adenocarcinoma of the ovary. The PCR result obtained from a normal ovary is also 
shown (not from the same patient). Tissue was collected and snap frozen 
immediately after surgery, mRNA extracted (p77), reverse transcribed (p83), and 
PCR performed (p90). Photograph shows PCR products on an agarose slab gel on 
which electrophoresis was performed (p97), staining following electrophoresis was 
carried out with ethidium bromide. Film used for photography was polaroid 665 and 
the exposure time for the photograph was 25s. A detailed description is given 
overleaf. 
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Description of Figure 3.11: Lanes I and 14 are molecular size markers, observed 
as 8 bands of masses: 1353 base pairs (bp), 1078 bp, 872 bp, 603 bp, 310 bp, 281 
bp, 234 bp, 194 bp. 
Lane 2: Sample from ovarian tumour probed for IL 1 a. I band observed approx. 
324 bp, expected size for ILl a PCR product, band considered positive result for 
IL l a. 
Lane 3: Sample from ovarian tumour probed for IL 1 ß. 1 band observed approx. 
376 bp, expected size for ILIß PCR product, band considered positive result for 
ILIß. 
Lane 4: Sample from ovarian tumour probed for IL6. No bands observed, 
considered negative result for IL6. 
Lane 5: Sample from ovarian tumour probed for TNFa. No bands observed, 
considered negative result for TNFa. 
Lane 6: Sample from ovarian tumour probed for TNFß. No bands observed, 
considered negative result for TNFß. 
Lane 7: Sample from ovarian tumour probed for ß2M. 1 band observed approx. 
322 bp, expected size for ß2M PCR product, band taken as positive result for ß2M. 
Lane 8: Sample from normal ovary probed for IL1 a. No bands observed, negative 
result for IL I a. 
Lane 9: Sample as for (8), but probed for IL I B. No bands observed, negative result 
for IL I B. 
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Description of Figure 3.11 Cont.: 
Lane 10: Sample from normal ovary probed for IL6. No bands observed, 
considered negative result for IL6. 
Lane 11: Sample from normal ovary probed for TNFa. No bands observed, 
considered negative result for TNFa. 
Lane 12: Sample from normal ovary probed for TNFß. No bands observed, 
considered negative result for TNFß. 
Lane 13: Sample from normal ovary probed for ß2M. 1 band observed approx. 322 
bp, expected size for ß2M PCR product, band considered positive result for ß2M. 
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3.4: Immuno-Histology Experiments. 
The results of the PCR experiments gave an indication of the patterns of 
cytokine expression in each tumour type. However the information was derived 
entirely from cDNA transcript analysis and so satisfactory conclusions could not be 
drawn from this material alone. There is always the possibility that any detected 
cDNA has been reverse transcribed from spurious mRNA and not translated into the 
protein. Production of the correct mRNA might not mean production of the protein. 
Also, assuming the tumour cells were producing the protein, the PCR results do not 
show the source of the detected cytokine, or the types of cell that are present in the 
tumour. There is always the possibility that the detected cytokines are being 
produced by infiltrating lymphocytes in the tumour and are not tumour cell derived. 
3.4.1 Immuno-histological Experiments Using Indirect Immuno-Fluorescence 
A series of immuno-fluorescent staining experiments were undertaken. It was 
decided to examine only those cytokines which had occurred most frequently in the 
PCR results, IL lc and IL6, and only samples which were positive for these in the 
PCR experiments were chosen. 
No normal breast tissue was used as it was found to be fatty and difficult to 
section adequately, no ovarian tissue was used due to the lack of material. A 
number of frozen tissue sections were prepared from each sample. 
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Each sample was to be stained for IL1 a and IL6 and also with phenotyping 
antibodies. These were antibodies for the cell surface markers 
CD8 (Cytotoxic/ 
Suppressor T-lymphocytes), CD14 (macrophages) and CD 21 (Activated B- 
lymphocytes). A series of experiments, using sections prepared from each sample 
chosen, was carried out to optimise the dilutions for each primary antibody. 
Dilutions of 1: 2000 to 1: 8000 were used for each antibody. A 1: 4000 dilution was 
optimal for the anti-ILla, anti-IL6 and anti-CD antibodies. The secondary antibody 
was employed at the manufacturer's recommended dilution (see methodologies for 
details). Negative controls were used for each set of sections, each being a section 
stained with PBS instead of primary antibody, but stained with secondary antibody. 
Each negative control demonstrated minimal fluorescence. A positive result was one 
in which there was noticeable fluorescence compared to that seen with the negative 
controls. Cells grown on cover-slips at standard conditions (see p) were stained for 
IL Ia and IL6. Both the MCF-7 and T-24 cell lines gave positive responses for these 
cytokines, but only the results for the MCF-7 cell line were bright enough to 
photograph. These are shown in figures 3.12-14. For the frozen sections, those 
samples which stained positive did not give fluorescence bright enough or long- 
lasting enough to photograph, although for each result the fluorescence was clearly 
brighter than that seen on the negative controls and was cell-associated. The results 
independently verified by a skilled histologist who confirmed their unsuitability for 
photography. They are shown in table 3.1 overleaf. 
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Table 3 .1 
Results of the Immunohistology Experiments Using Indirect Immuno- 
Fluorescence. 
Cell Line or IL Ia IL6 Antibody CD8 Marker CD 14 Marker CD21 
Tumour Antibody (Cytotoxic/ (Activated B- Marker 
Type' Suppressor T- Cells) (Activated 
Cells) B-Cells) 
MCF-7 Cell Strong + Stong + N. A. N. A. N. A. 
Line 
T-24 Cell + + N. A. N. A. N. A. 
Line 
Breast - + + + + 
Tumour 4 
Bladdder + + - - + 
Tumour 2 
Lung - + + + + 
Tumour 4 
Non- - + + + + 
malignant 
Lung 4 
N. A. = Not Applicable 
Only I sample of each type probed, number is identifier used on tables 3.3-3.13 
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Figure 3.12: MCF-7 cells stained for ILIa using indirect immuno-fluorescence. 
Objective magnification x 40, film speed ASA 400. 
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Figure 3.13: MCF-7 cells stained for IL6 using indirect immuno-fluorescence. 
Objective magnification x 40, film speed ASA 400. 
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Figure 3.14: MCF-7 cells stained with haematoxylin and eosin. Objective 
magnification x 10, film speed ASA 400. 
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Table 3.2: Results of Immuno-histology Experiments Performed on Paraffin -Embedded 
Sections Using an Alkaline Phosnhatase conjugated Secondary Antibody. 
CD68 
Tumour IL1 Alpha 1L6 (macrophage 
Type 
marker) 
Breast 
Tumour 10 
+ + + 
Breast 
+ + N. D. Tumour 11 
Breast 
+ + N. D. Tumour 12 
Breast 
+ + N. D. Tumour 13 
Breast 
++N. D. Tumour 14 
Bladder 
weak + Tumour 14 -- 
Lung 
Tumour 7 
#Non- 
malignant - + + 
Lung 7 
*Non- 
malignant - - N. D. 
Lung 8 
Notes: #Non-malignant lung 7 from same patient as lung tumour 7 
*No lung tumour 8 (lung tuberculated) 
3 
.42: 
Immuno-Histological Experiments Using An Alkaline Phosphatase- 
Conjugated Secondary Antibody Carried Out on Paraffin-Embedded Sections. 
The previous set of experiments had demonstrated that ILla and IL6 
proteins could be detected in tumour samples which gave positive results when 
probed for these cytokines by PCR. However, although the results of the 
experiments could be independently verified, they could not be presented in this 
thesis in photographic form (apart from the results for the MCF-7 cell line). Nor 
could the results determine in which type of cells the cytokines originated. A 
new series of experiments was undertaken. These used a different immuno- 
histological technique to investigate the presence of ILl a and IL6. This was one 
which could be performed on paraffin-embedded sections and it used an alkaline 
phosphatase-conjugated secondary antibody. This antibody, when developed 
gives positive results which are permanent and which, if the slide is counter- 
stained with haematoxylin, will show what cell type the stained protein is 
associated with. The stained material can be seen in the cellular cytoplasm in the 
golgi body. In this way, any positive results for IL 1a and IL6 would also give 
the cell type of origin. The previous set of experiments used only material in 
which IL 1a and IL6 were expected. To compensate for this, in these experiments 
all of the tissue chosen was not previously subjected to PCR, and so there was 
no expectation of what cytokines would be detected in what tissue. The results 
of the experiments are shown in table 3.2 opposite, and photographs of the best 
results given in figures 3.15-3.25. 
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Figure 3.15: Breast Tumour 10 stained for ILl a using an alkaline phosphatase 
conjugated secondary antibody. A strong positive result (red staining) can be 
seen in the large ductal cells in the centre of the picture. Objective magnification 
is x40 and film speed ASA 160, with a tungsten light source. 
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Figure 3.16. Breast Tumour 10 stained for IL6 using an alkaline phosphatase 
conjugated secondary antibody. A strong positive result (red staining) can be 
seen in the large ductal cells in the centre of the picture. Objective 
magnification is x40 and film speed ASA 160, with a tungsten light source. 
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fire 3.17: Breast Tumour 10 stained with only the secondary antibody and 
then haernatoxylin and eosin as a negative control, area shows large ductal cells. 
Objective magnification is x40 and film speed ASA 160, with a tungsten light 
source. 
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Figure 3.18: Breast Tumour 10 stained for CD68 (macrophage marker). Area 
shows positive-staining macropages around large ductal cells, but these 
macrophages are not in the same region of the tissue as the IL1 a or IL6-positive 
stained areas shown in figures 3.15 and 3.16. Objective magnification is x25 and 
film speed is ASA 160, with a tungsten light source. 
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Figure 3.19: Bladder Tumour 14 stained for IL1 a using an alkaline phosphatase 
conjugated secondary antibody. A positive result (red staining) can be seen in 
two cells in the centre of the picture. Objective magnification is x40 and film 
speed ASA 160, with a tungsten light source. 
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Figure 3.20: Bladder Tumour 14 stained with only the secondary antibody and 
then haematoxylin and eosin as a negative control. Objective magnification is 
x10 and film speed ASA 160, with a tungsten light source. 
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Figure 3.21: Lung Tumour 7 stained for IL6 using an alkaline phosphatase 
conjugated secondary antibody. A positive result (red staining) can be seen in the 
large cell in the centre of the picture. Objective magnification is x40 and film 
speed ASA 160, with a tungsten light source. 
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Figure 3.22: Lung Tumour 7 stained with only the secondary antibody, and then 
haematoxylin and eosin, as a negative control. Area shows similar large cells to 
those which stained positive for IL6 in figure 3.21 Objective magnification is 
x25 and film speed ASA 160, with a tungsten light source. 
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Figure 3.23: Non-malignant Lung 7 stained for IL6 using an alkaline phosphatase 
conjugated secondary antibody. A positive result (red staining) can be seen in 
some of the large surface cells, especially in the centre of the picture. Objective 
magnification is x40 and film speed ASA 160, with a tungsten light source. 
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Figure 3.24: Non-malignant lung 7 stained for CD68 (macrophage marker). 
Macrophages can be observed as red staining cells scattered over the field. They are 
of a different morphology to the IL6- positive cells shown in figure 3.23. Objective 
magnification is x25, film sped ASA 160, with a tungsten light source. 
wiflM 
170 
1 
ýaº, ý. 
i` .ý r, -tý 
wýý1 
rý ýý ýT ý 
" 48 f 
. 
ý. 'ý 4, L - 
ý n% 
am 
it- fV 1ý 
fIA. 0% 1* 14h 
I *7 
N If Wl 
. lir ! 
_Ampr_ a. 4ý 1 ýt -a 
JF ý. ý ý, 
ýý %w. Jý' 
. 
ýý 
ri ._: 
plý-. l 'TI º 
-- - -i ". 
: L. ft 
ý. ý1-W!, or `-aý 'ý. º Timm* w º, w_ -41ý ALR - '. %. -Jokk i.... I- .! 
.., iw R# V A" 404m:! w q _. 6k ýý ýºý ýzk 
M #* Ir", gw a. %%wfk, !" deArm. 
-2 
"-ý 
lp 
qqr -, tvý`,, ýýý 
.. ýº. ,-ý(`fý, 
ý 
. ý" 
ýý 
ý/ý s ti '" 
. -' Alt 
ý ý;. f ý. ý, ýýýý". ýý 
ý. ýý #: w, a 
Figure 3.25: Close-up of non-malignant lung 7 stained for CD68 (macrophage 
marker). Macrophages can be observed as red staining cells scattered over the field. 
They are of a different morphology to the IL6- positive cells shown in figure 3.23. 
Objective magnification is x40, film sped ASA 160, with a tungsten light source. 
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3.5: Investigation of Patients' Medical Records. 
An investigation of the medical records of the patients supplying tumours for both 
the PCR portion of the research, and the immuno-histological part of the research 
was carried out. Records of all the patients giving positive PCR results were 
checked where possible. This was also carried out for the patients supplying 
tumours for the experiments using immuno-histology on paraffin-embedded 
sections. For various reasons not all of the records were available and so could 
not be consulted. The information from the records was collated into tables. The 
first table gives general clinical information, the second biochemistry and 
haematology information, and the last table gives individual cytokine profiles for 
each sample examined. In the tables showing the biochemistry and haematology 
results, the levels of c-reactive protein and the erythrocyte sedimentation rates 
could not be reported as these were not measured routinely. 
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Table 3.3: Clinical Results From Records of Breast Tumour Patients 
Temp. on Tumour Weight Loss: Pathology of Tumour 
Appetite: Day of Adm. 
Type Yes/No Poor/Good (degrees C) 
Breast Invasive Ductal Cell Carcinoma 
Tumour 1 
Yes 
(Bloom + Richardson II) 
poor 36 
Breast Mucinoid Carcinoma of Breast with 
Tumour 2 Surrounding Interductal Carcinoma 
N. A Poor 36.7 
Breast Intraductal and Invasive Breast 
Tumour 3 carcinoma (Bloom + Richardson II) 
N. A Good 36.2 
Breast In-situ and Infiltrating Ductal Cell 
Tumour 4 
No Good 
Carcinoma (Bloom + Richardson III) 
36.4 
In-Situ Ductal Cell Carcinoma, and Breast 
seperate Invasive Ductal Darcinoma Yes Poor 36.6 Tumour 5 (Bloom +Richardson III) 
Breast Paget's Disease of Left Nipple and N. A. Good 36 Tumour 6 Intraductal Carcinoma 
Breast Intraductal and Infiltrating N. A. N. A. 36.2 
Tumour 7 carcinoma (Bloom +Richardson II) 
In-situ and infiltrating moderately 
Breast well differentiated ductal carcinoma 
Tumour ,8 of the breast (Bloom + Richardson 
No Good 36 
II)_ j 
Breast Intra-ductal and infiltrating ductal 
carcinoma (grade I) No involvement N. A. Good 36 Tumour 10 
of lymph nodes 
Breast Infiltrating grade III ductal 
Tumour 11 carcinoma with a prominent N. A. Good 37 
lymphocytic reaction to the tumour 
lobular carcinoma in situ associated Breast 
Tumour 12 with infiltrating breast carcinoma N. A. Good 36.5 
(grade II) 
Infiltrating lobular carcinoma (grade t ýýt. No (had 
tumour 13 
11) with foci of lobular carcinoma in- 
gain 
Good 36.5 
situ 
Notes: 1) Bloom + Richardson is grading system. Higher no. = higher grade 
2) Records for breast tumours 9 and 14 were unavailible. 
3) N. A. = Not Availible 
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Table 3.4: Clinical Results from Records of Bladder Tumour Patients 
Temp. on 
Tumour Pathology of Tumour Weight Loss: Appetite: Day of Adm. 
Type Yes/No Poor/Good (degrees Q 
Bladder 
Tumour I 
well-differentiated papillary transitional cell N. A. 
Good, but 
35.5 
carcinoma Small (male) 
Bladder Invasive poorly-differentiated transitional cell 
Tumour 2 carcinoma (Ash IV)4 with focal squamous Yes Poor 36.8 
(male) differentiation 
Bladder Papillary transitional cell carcinoma(Aah 
Tumour 3 IIl)with areas of infarction, and invasion of the No Good 36.2 
(male) superficial 
lamia propria 
Bladder Mainly papillary superficial transitional cell 
Tumour 4 carcinoma (Ash II) with no evidence of sub- No Good 36.2 
(female) mucosal 
invasion 
Bladder Moderately-well differentiated transitional cell 
Tumour 5 carcinoma (Ash II) with one focus of early No Good 36.2 
(male) stromal invasion 
Bladder 
Tumour 6 
Well-differe bated papillary transitional cell N. A. Good 36.3 
carcinoma, with no invasion of underlying tissue 
(male) 
Bladder Superficial transitional cell carcinoma (Ash II) 
Tumour 7 which is mainly papillary. No evidence of No Good 35.7 Invasion of sub-mioosa or muscle. Mild chroni c 
(male) inflammation present. 
Bladder Well-differentiated papillary transitional cell 
Tumour 8 carcinoma with focal superficial invasion of the N. A. Good 36.5 
(male) underlying stroma (Ash II). 
Bladder 
Tumour 9 Papillary transitional cell carcinoma (Ash II- N A Good 36 2 III), with focal invasion of the submucosa) . . . 
male 
Notes: 1) Ash is grading system. Higher no. = higher grade 
2) Only results for Bladder tumours 1- 9, are shown. Records for rest were unavailible. 
N. A. = Not Availible 
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Table 3.5: Clinical Results from Records of Lung Tumour Patients 
Tumour 
Temp. on 
I Weight Loss: Appetite: Day of Adm. Pathology of Tumour Type Yes/No Poor/Good (degrees C) 
Lung Poorly-differentiated mucus- 
Tumour 1 
secretory adenocarcinoma 
No Good 36 
(male) 
Lung Moderately -differentiated squamous Tumour 2 
carcinoma arising in a bronchus 
Yes Good 36.1 
(male) 
Invasive moderately-differentiated Lung 
squamous carcinoma arising from Tumour 3 No Good 35.8 disrupted and ulcerated mucosa of (male) 
the upper second order bronchus 
Lung Moderately-differentiated squamous Tumour 4 No Good 36.5 
(male) carcinoma 
Lung Invasive large cell anaplastic Tumour 5 
carcinoma of the bronchus 
N. A. Good 36 
(male) 
Lung 
Bronchial carcinoid tumour 
Tumour 6 composed of packets and trabeculae Yes Poor 36.5 
(female) of eosinophilic cells with open 
nucleai 
Notes: 1) Records for lung tumour 7 were unavailable. 
2) N. A. = Not Availible 
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Table 3.6: Clinical Results from Records of Ovarian Tumour Patients 
Tumour iI 
of Tumour 
Weight Loss: Appetite: 
Temp. on 
Day of Adm. ype Type Yes/No Poor/Good (degrees C) 
Papillary Adenocarcinoma with Malignant 
numerous calcospherocytes Ovarian 
consistent with metatastic spread 
No Poor 36.5 
Tumour 1 from an ovarian primary 
Malignant 
Papillary Adenocarcinoma with 
numerous calcospherocytes No Good 36 
Tumour 2 consistent with metatastic spread from an ovarian primary 
Normal Right Ovary containing a theca No Good 36 Ova 1* i lutein c st 
Notes: * Not from same patient as Ovarian Tumour 1 
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Table 3.7 (overleaf): This table shows the results taken from the biochemical and 
haematological analyses preformed on the breast tumour patients on the day prior to 
surgery. The records for patients 9 and 14 were unavailible. Only brest tumour 5 had 
elevated serum levels of calcium (2.72 mmol/1) This tumour expressed IL6 only. No 
patients displayed abnormal globulin levels. Breast tumours 2 and 6 had elevated 
white blood cell counts (17.5 and 12 x109 cells/ I respectively)However, neither of 
these patients had expression for any cytokine. All patients had normal lymphocyte, 
monocyte and platelet counts, except for breast tumour 6, which had an elevated 
platelet count of 471 x109 cells / 1. In the table 1 x10" is given as 1x 10 exp X, and 
N. A. = not availible. 
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Table 3.8 (overleaf): This table shows the results cells taken from the 
biochemical and haematological analyses performed on the bladder tumour 
patients on the day before surgery. The records for bladder tumours 10 - 14 were 
unavailible. No bladder tumour patients had elevated levels of calcium in serum, 
or elevated levels of globulins. In the haematological analysis, bladder tumour 
2 had an elevated white blood cell count (13.3 x109 cells / 1) and bladder tumour 
3 had an elevated platelet count (648 x 109 cells % 1) all other bladder tumour 
patients had normal white blood cell, neutrophil, lymphocyte, monocyte, and 
platelet counts. Bladder tumour 2 expressed IL Ia and IL6, but bladder tumour 
3 expressed no cytokines. 
In the table, I x10" is shown as 1x 10 exp X. 
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Table 3.9 (overleaf): This table shows the results cells taken from the 
biochemical and haematological analyses performed on the lung tumour patients 
on the day before surgery. All of the lung tumour patients had normal levels of 
calcium in serum, and all had normal levels of globulins except lung tumour 6, 
which had a globulin level of 46 g/1. This tumour expressed IL6. Lung 
tumours 3,4, and 6, expressed high white blood cell counts (17.7 x 109 cells / 1, 
14.8 x109 cells ' 1, and 14.9 x109 cells /1 respectively), and high neutrophil 
counts (15.7 x109 cells / 1,7.65 x109 cells /I and 13 x109 cells /I respectively) 
Lung tumours 3,4, and 6 expressed IL6. IL6 was expressed in the non- 
malignant lungs of lung tumour patients 4 and 6. No platelet counts were 
available for the lung tumour patients. 
In the table, Ixl Ox is shown as 1x 10 esp X. 
N. A. = not available. 
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Table 3.10 (overleaf): This table shows the results cells taken from the 
biochemical and haematological analyses performed on the ovarian tumour 
patients on the day before surgery. No patients have elevated calcium 
concentrations or globulin concentrations in their serum. Malignant tumour 
patient 1 has an elevated white blood cell count and an elevated platelet count. 
In the table, I x10" is shown as 1x 10 exp X. 
N. A. = not availible. 
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Table 3.11: Cytokine Profiles for Breast Tumours. 
Tr IL-1 Alpha IL-1 Beta 11-6 TNF Alpha TNF Beta Beta -2 M 
Breast 
Tumour 1 + 
Breast 
Tumour 2 - - - - - + 
Breast 
Tumour 3 - - - - - + 
Breast 
Tumour 4 
+ 
Breast 
Tumour 5 + - - + 
Breast 
Tumour 6 - - + 
Breast 
--+ Tumour 7 ++ 
Breast ----- 
Tumour 8+ Ii -+ 
Breast 
Tumour 9- _ + + + + 
Breast 
Tumour 10* + N. D. + N. D. N. D. N. D. 
Breast 
Tumour 1 1* + N. D. + N. D. N. D. N. D. 
Breast 
Tumour 12* + N. D. + N. D. N. D. N. D. 
Breast 
Tumour 13* + N. D. + N. D. N. D. N. D. 
Breast 
Tumour 14* + N. D. + N. D. N. D. N. D. 
Notes: * These profiles were obtained from the second set of immuno-histology experiments, not from PCR 186 
3.12: Cytokine Profiles For Bladder Tumour Samples 
Tumour IL-1 Alpha IL-1 Beta IL6 TNF Alpha TNF Beta Beta -2 M Type 
Bladder 
Tumour 1 + - + 
Bladder + 
Tumour 2 - 
+- - + 
Bladder 
Tumour 3- - - - - + 
Bladder 
Tumour 4- - + - + 
Bladder 
Tumour 5 -- - + 
Bladder 
Tumour 6 - + 
--- Bladder 
Tumour 7++ + 
Bladder 
_ Tumour 8 - + - + 
Bladder 
Tumour 9 
Bladder 
Tumour 10 + +! - + 
Bladder 
Tumour 11 + - + 
Bladder 
Tumour 12 - - -- - + 
Bladder 
Tumour 13 - - + 
Bladder 
Tumour 14* N. D. N. D. N. D. N. D. N. D. 
Notes: *Profile for Bladder tumour 14 from second set of Immuno-histology experiments, not from PCR 
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Table 3 13: Cytokine Profiles for Lung Tumour Samples and Samples of Non- Malignant 
Lung From the Same Patients 
Tumour 
Type 
IL-1 Alpha IL-1 Beta IL6 TNF Alpha TNF Beta Beta -2 M 
Lung 
Tumour 1 + + + 
Lung 
Tumour 2 + 
Lung 
Tumour 3 + - - + 
Lung 
Tumour 4 _ + - - + 
Lung I 
_- Tumour 5 + - + 
Lung ------------- ---------- ------------ 
Tumour 6 + -- + 
Non- 
Malignant 
Lung Sample _ 
I 
Non- 
Malignant 
Lung Sample - - + 
2 
Non- 
Malignant 
Lung Sample - - - 
3 
Non- 
Malignant 
Lung Sample + - + 
4 ) 
Non- 
Malignant 
Lung Sample + 
5 
Non- 
Malignant 
Lung Sample + - - + 
6 
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3.6: Effects of IL6 on the Growth of the Cell Lines. 
A series of experiments were carried out to investigate the effect of IL6 on 
the cell lines. The first experiment consisted of a study of the effects of IL6 
(overall the most commonly detected cytokine) on the breast cell line, MCF-7. 
The method used is described on p 115. The experiment studied the effect of a 
set dose of crude IL6 on a population of MCF-7 cells over 96h. The results are 
shown in figure 3.26 Two separate populations were used, a control group, and 
a population treated at the start of the experiment with 36 U/ml of crude IL6. 
Both cell concentrations were initially 3000 cells/mi. Over the course of the 
experiment the line derived from the control population demonstrated an 
exponential growth curve typical of uninhibited cell growth. In contrast the 
growth curve for the treated cells, flattened out after 72h; this is typical of growth 
inhibition. 
A follow-up experiment was carried out to determine if this apparent 
inhibition was due to IL6 and if it was dose responsive. The result is shown in 
figures 3.27 and 3.28. The method used to measure growth was different, as 
detailed on p115. Cell numbers were estimated by dye absorbance. The greater 
the number of cells, the greater is the absorbance. 
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The B-9 cell line was used as a positive control as it was known that 1L6 causes 
dose-dependent growth of this cell line. 
Figure 3.27 represents the results after 48 h and figure 3.28 is the results after 
72h. The two time values were chosen as figure 3.26 showed that MCF-7 cell may 
be inhibited by the IL6 initially at 48h, and was definitely inhibited after 72h. For 
precision, recombinant IL6 was used at concentrations ranging from 0-100 pg/ml. 
Each cell line was used at an initial concentration of 5x 104 cells/ ml. On figure 3.27, 
at 48 hours, the concentrations of cells for each cell line is different, due to each cell 
line having a different rate of growth. However all the lines are more or less flat, 
with little significant deviation from the concentration of the untreated population. 
The IL6 is having no apparent effect on growth of any of the cell lines at any IL6 
concentration after 48h. On figure 3.28, the results after 72h, cell numbers of all the 
cell lines, even those with no IL6 have increased, again due to another 24h of growth. 
The growth curve for the T-24 cells was still flat showing no effect of IL6 on these 
cells after 72h at any concentration. The growth curve for the B-9 cells showed a 
rising trend as the dose of 1L6 increased, showing possible growth stimulation. The 
growth curve for the MCF-7 cell line shows a downward trend at IL6 concentrations 
greater than 50 pg/ ml: IL6 may be inhibiting the growth of MCF-7 cells at these 
high concentrations after 72h. 
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Figure 3.26: Effects of IL6 on the Growth of MCF-7 Cells Over 96 h. 
IL6 Added 
No IL6 Added 
0 24 48 
Time (h) 
72 96 
Note: Exp = "to the Power of', e. g. 1x 10 exp 3= 1000) 
Figure 3.26 (Opp): Effects of Crude IL6 on the Growth of MCF-7 cells Over 
96h. 
The procedure for this experiment, the medium used and the culture conditions 
are given on page 115. Both initial cell populations were 3000 cells / ml. 
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Figure 3.27: Effects of Increasing Concentrations of Human Recombinant IL6 on the T-24, 
MCF-7, and B-9 Cell Lines After 48h. 
0.4 
0.35 
0.3 ý- 
0.25 
0.2 
--f-- T-24 
0--- MCF-7 
- *- - B-9 
_J 
0.15 
0.1 
0.05 
0 
/ 
0 12.5 25 50 100 
IL6 Concentration (pg/ml) 
Figure 3.27 O Dill Effect of Increasin (I Concentrations m of Human 
Recombinant IL6 on the T-24, MCF-7, and B-9 Cell Lines After 48h. 
The procedure for this experiment, the medium used and the culture conditions 
are given on page 115. Cell concentrations were evaluated as a function of 
absorbance as measured on a standard plate reader at 520 nm. Each point on the 
graph is individual, and not a mean. For this reason no error bars are plotted. 
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Figure 3.28: Effects of Increasing Concentrations of Human Recombinant IL6 on the T-24, 
\ICf - and B-9 Cell Lines After 72h. 
0.45 
-- - T-24 
- MCF-7 
-- f- B-9 
0.15 + 
0.1 + 
0.05 ý 
0 
0 12.5 25 50 100 
IL6 Concentration (pg/ml) 
Fissure 3.28 (Opp. ): Effect of Increasing Concentrations ()g/ml) of Human 
Recombinant IL6 on the T-24, MCF-7, and B-9 Cell Lines After 72h. 
The procedure for this experiment, the medium used and the culture conditions 
are given on page 115. Cell concentrations were evaluated as a function of 
absorbance as measured on a standard plate reader at 520 nm. Each point on the 
graph is individual, and not a mean. For this reason no error bars are plotted. 
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Chapter 4: Discussion. 
4.1 General: 
The investigations presented in this thesis were prompted by reports that some 
tumours could produce inflammatory cytokines. Miyauchi et al (1988) had reported the 
in vitro production of IL I by 16 cell lines of various types, and Kock et at (1988) 
demonstrated IL I production by malignant melanoma cell lines. In an in-vivo study, 
Sato et al (1987) found a factor with IL 1-like bio-activity in serum from a patient with 
thyroid carcinoma. The T-24 bladder epithelial cell line was found to produce IL6 by 
Yasukawa et at (1987) and in-vivo production of IL6 was detected by Meyers et at 
(1991) in high grade bladder tumours. Expression of IL6 was also detected in renal 
carcinoma cell lines and solid renal tumours (Miki et al, 1989; and Takenawa et al, 
1991). Tabibzadeh et al (1989) detected IL6 by immuno-histology in primary squamous 
cell carcinomas of colonic, ovarian, and endometrial origin. TNFa expression was 
reported in various cell lines including ovarian and lung (Spriggs et al, 1988; Kronke et 
al 1988) and it was detected in-vivo in high concentrations in the serum of 
approximately 70% of patients with ovarian and oat-cell carcinomas by Balkwill et at 
(1987). 
The aim of the research presented here was to expand this work by examining 
whether the inflammatory cytokines could be produced in-vivo by some common 
tumour types. To this end methods were developed to detect the inflammatory cytokines 
in primary samples of tumours. 
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It was hoped that if this work were to be successful, it might lead to the development of 
one or more of the inflammatory cytokines as a tumour marker. The types of tumour 
chosen had not, at the time of commencement of the research, been previously examined 
for cytokine production. They were also readily and frequently available. 
The methods chosen for cytokine detection were PCR followed by two types of 
immuno-histology. PCR was chosen, despite the possible difficulties of analysing 
mRNA discussed later, because of its specificity and rapidity. One PCR experiment 
could simultaneously profile the entire inflammatory cytokine expression of several 
tumours in a few days. Immuno-histology was performed on a limited number of 
tumours to check the results obtained in the PCR experiments and ensure that detected 
cytokine mRNA was being translated into protein. Examination of tumour sections by 
indirect immuno-fluorescence using an FITC-conjugated secondary antibody was 
chosen initially because of its sensitivity. At a later stage a method employing an 
alkaline-phosphatase conjugated secondary antibody was used because the immuno- 
fluorescence method did not give photographically recordable results for some tumours 
and could not show cell morphology clearly. 
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4.2: Cytokine Production by Breast Tumours. 
4 
. 
2.1 Cytokine production by a Breast Cell Line: 
When the breast cell line MCF-7 was examined in the PCR study, mRNA for 
M cc, a, IL 1 ß, and IL6 was detected. In the indirect immuno-fluorescence experiments, there 
was a strong positive result for IL 1a and IL6. The result for IL6 is partly corroborated by 
a report that a cell line similar to the MCF-7, the T-47D cell line, produces IL6 detectable 
by immuno-histology (Tabibzadeh et al 1989). 
4.2.2 Cvtokine Production in the Breast Tumours as Detected by PCR: 
Twenty breast tumour samples were collected and snap frozen in liquid nitrogen as 
soon as possible after removal. Of these, 9 tumours had intact mRNA as determined by 
positive ß2 microglobulin. Seven of these tumours were invasive ductal cell carcinomas of 
Bloom and Richardson grade II or 111, one was an intraductal carcinoma one a mucinoid 
carcinoma and the last was of unknown type (its' record was unavailable). Non-malignant 
breast tissue was also collected from each patient for use as positive controls. None of this 
material had intact mRNA despite numerous attempts to extract it and re-evaluation of the 
methodology using macrophage-derived mRNA. PCR profiling of the 9 intact tumour 
samples showed no ILIu or ILIß, but detection of IL6 in 5 tumours, TNFu in 2 tumours, 
and TN Fß in 1 tumour. 
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4.2.3 Cytokine Production in Breast Tumours as Detected by Indirect Immuno- 
fluorescence. 
Frozen sections of breast tumour 4 were selected for the immuno-fluorescence 
experiments. Staining was carried out for IL 1a and IL6 only, because from the PCR 
profiling of all tumour types these were the most frequently observed cytokines. From 
the cytokine profile obtained from PCR analysis, breast tumour 4 was expected to give a 
negative result for IL 1a but a positive result for IL6. As expected breast tumour 4 was 
observed to fluoresce only when stained for IL6. However, the fluorescence was not of 
sufficient duration for photographic recording (the result was independently witnessed). 
Subsequently, indirect immuno-fluorescence was also performed on other sections of 
breast tumour 4 to examine the degree of T-cell, B-cell, and macrophage infiltration in 
the tumour (using antibodies to the cell surface markers CD8, CD2 1, and CD 14 
respectively). All three types of lymphocyte were detected in the tumour (again 
fluorescence was too unstable to photograph) and all three lymphocyte types could 
potentially be the source of the detected IL6. However, since the indirect immuno- 
fluorescence technique does not show cell morphology clearly (see fig 3.12 p157) it 
could not be determined whether the IL6 expression was tumour-cell associated or 
lymphocyte associated. Preparation of frozen sections of non-malignant breast from 
breast tumour patient 4 was attempted, but was unsuccessful due to the tissue containing 
a high proportion of fat, which dissolved during the mounting process, removing the 
tissue as well. 
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4.2.4: Cytokine Production in Breast Tumours as Detected by Immuno-histology using 
an Alkaline Phosphatase-Conjugated Secondary Antibody. 
The short duration of fluorescence observed with positive results for breast 
tumour 4 was repeated with sections of other tumour types subjected to the same 
technique. Therefore a new immuno-histology technique was adopted. This used the 
same primary anti-cytokine antibodies but a different secondary antibody. This was an 
alkaline-phosphatase conjugate capable of giving positive results of a permanent nature 
observable by an ordinary light microscope. Positive staining tissue would show as a 
bright red colour once reacted with the "fast red" enzyme substrate. Sections could also 
be counter-stained to highlight cell morphology. 
Unfortunately, before any of these experiments could be performed, a power 
failure resulted in spoilage of the original frozen tumour samples. The tissue archives 
kept by the hospital pathology department did have paraffin-embedded samples of the 
tumours. However after expert consultation, the amount of material left in each sample 
was judged inadequate for use so a new set of tumour samples had to be collected. 
Improvements in the immuno-histological technique meant that it could be used 
on paraffin-embedded sections. Using tissue in this way made sample collection 
simpler, as material could be placed in formalin by the surgeon or pathologist as soon as 
possible after removal and uplifted for further processing later. Paraffin-embedded 
tissue also offered more secure long-term storage. 
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However the immuno-histology technique required modification by using the primary 
antibodies at higher concentration. 
Five breast tumours were collected and subjected to the new immuno-histology 
method. While it was intended to collect non-malignant breast tissue from the same 
patients, this was not possible as in each case the tumours were so large compared to 
surrounding tissue that the pathologist could not supply tissue which was guaranteed 
tumour-free. Three of the tumours were infiltrating ductal cell carcinomas (of grades 
Bloom and Richardson I, III and II respectively) and the other two infiltrating lobular 
carcinomas (both grade II). All five tumours gave clearly positive results when stained for 
ILla and IL6. In both cases the positive staining was observed in some large ductal cell 
structures and surrounding stroma. Staining of the five samples using an anti-macrophage 
marker (the CD68 marker, chosen because it was more sensitive than the CD14 marker 
used previously) showed that these were present in at least one of the tumour samples but 
were not associated with the regions of ILla or IL6 expression. 
While expression of IL6 by the breast tumours correlated with the results obtained 
from the first group of tumours using PCR, expression of ILIa by the new collection of 
tumours did not correlate with these results as its expression was not seen in any of the 
tumours in the PCR group. PCR was not performed on any of the new tumours as they 
had all been fixed in formalin, which renders it very difficult to extract intact mRNA.. 
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Because of this, the conflict between the lack of IL Ia expression detected in the first 
group of tumours and the expression detected in the second group of tumours could not 
be adequately resolved. 
It is probable that some of the tumours in the PCR group had a low level of IL Ia 
expression. The PCR technique was based on bulk analysis of mRNA in the whole 
sample. RNA is easily degraded and often present at low concentrations so the PCR 
technique may not have been sufficiently sensitive to detect small amounts of cytokine 
mRNA compared to high background levels of non cytokine material. It must be 
remembered that of the 20 samples collected for PCR analysis, just under half expressed 
ß2-microglobulin, and approximately half of these expressed IL6. ß2-microglobulin 
should be expressed by all of the nucleated cells in all of the samples, but was not, 
indicating possible lack of sensitivity or ability to extract intact mRNA. If IL6 was 
being expressed (and this is suspected from the immuno-histology results) then it might 
be detected in some of these tumours but low level expression of IL Ia might be beyond 
the detection limit of the PCR technique. 
By contrast, the immuno-histology technique not only detected cytokine protein, 
which is much more stable than mRNA, but was also able to do this with great 
sensitivity, on a cellular scale. Cytokine expression was detected in individual cells 
scattered in patches throughout the tumour sections, with some sections showing good 
detection of IL I a. 
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In balance therefore, it seems probable that the results of the immuno-histology 
experiments were more valid than those of the PCR experiments, and therefore the 
final conclusion for the breast material is that some large ductal cells in these tumours 
can express IL Ia and IL6. 
If a new study were to be performed (as outlined later) then the conflict between 
the results could be resolved by collecting both fixed and snap-frozen tissue and 
examining cytokine production in each group by both immuno-histology and PCR. 
This study would also include, wherever possible, non-malignant breast tissue from the 
same patients and non-malignant material from breast reduction mammoplasties (which 
would require the co-operation of a plastic surgery unit at another hospital). 
4.2.5 Examination of the Medical Records of the Breast Tumour Patients. 
The records of all of the patients donating tumour samples (where available) were 
examined for features which could be due to the systemic action of the inflammatory 
cytokines. As previously mentioned in the introduction (pp62-63, p67) there is some 
evidence for an association between cachexia (characterized by weight loss) and TNFa 
and IL6 expression in cancer patients and animal models. There is also an association 
between hypercalcaemia and IL I expression in some cancer patients (p 50). 
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General indicators of inflammation such as increased platelet counts, increased white 
blood cell counts and increased concentrations in serum of globulins were also 
examined, although much of the best information of this type e. g. concentrations in 
serum of acute phase proteins such as C-reactive protein (CRP) or erythrocyte 
sedimentation rates could not be used as they were not recorded in the patients' notes. 
Scrutiny of the available clinical records revealed that breast tumour patients 1 
and 5 had both weight loss and poor appetite. While breast tumour 5 expressed IL6, 
breast tumour 1 displayed no cytokine production. In the majority of the patients, 
weight loss was not recorded. Breast tumour patient 2 also had a poor appetite, but this 
patient's tumour displayed no cytokine expression. Breast tumour patients 4,8, and 13 
all had tumours expressing IL6, but showed no weight loss (breast tumour 13 showed 
weight gain). It appears that in all of the breast tumour patients, there was no correlation 
between tumour IL6 expression and weight loss. No correlations could be made 
between the TNFct expression in breast tumours 7 and 9 and weight loss as the records 
for the patients donating these tumours were either unavailable or made no record of it. 
Only breast tumour patient 5 had a raised serum concentration of calcium. The 
corresponding tumour was observed to express only IL6. No breast tumour patients 
expressed raised concentrations in serum of globulins. Breast tumour patients 2 and 6 
displayed elevated white blood cell counts and neutrophil counts, with breast tumour 
patient 6 also having an elevated platelet count. Neither patient had a tumour expressing 
any of the inflammatory cytokines. 
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In conclusion, while there was good evidence for the production of IL Ia and IL6 
in some of the breast tumours examined (probably by the tumour cells) and weaker 
evidence for the production of TNFa or TNFß in a few tumours, no correlation was 
demonstrable between the clinical features observed in the patients and systemic action 
of the inflammatory cytokines. 
43: Production of Inflammatory cytokines by a Bladder Cell Line and by Bladder 
Tumours. 
4.3.1 Cytokine production by a Bladder Cell Line: 
The bladder epithelial cell line T-24 was found to express IL 1a mRNA as 
determined by PCR. The first set of immuno-histology experiments (using indirect 
immuno-fluorescence) showed that it also expressed IL 1a protein, although the 
observed result was not long-lasting enough to photograph. Production of IL 1a by the 
T-24 cell line has also been demonstrated by Hayashi et al (1994) confirming the result. 
The bladder cell line also produced IL6, which was detected both by PCR and indirect 
immunofluorescence. This was a good positive control for both detection methods as 
this cell line is a known constitutive producer of IL6 (Yasukawa et al, 1987). 
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43 2 Cytokine Production in the Bladder Tumours as Detected by PCR: 
Twenty-one bladder tumours, all transitional cell carcinomas, were collected 
from patients undergoing cystoscopy. Of these, 13 gave detectable expression of ß2- 
microglobulin and were judged to have intact mRNA.. In these, 7 tumours expressed 
IL6,4 expressed IL I a, and 1 each expressed TNFa and TNFB. There appeared to be no 
correlation between cytokine expression and tumour grade or invasiveness, although the 
number of tumours examined was too small for meaningful correlations to be made. 
4.3.3 CXtokine Production in Bladder Tumours as Detected by Indirect Immuno- 
fluorescence. 
Frozen sections of bladder tumour 2 were selected for the immuno-fluorescence 
experiments. Staining was carried out for IL! a and IL6 only because from the PCR 
profiling of all tumour types they were the most frequently observed cytokines. From 
the cytokine profile obtained from PCR analysis, bladder tumour 2 was expected to give 
a positive result for both IL! a and IL6 and this was confirmed by the presence of 
fluorescence. However, the fluorescence was not of sufficient duration for photographic 
recording although the result was independently witnessed. Subsequently, indirect 
immuno-fluorescence was also performed on further sections of bladder tumour 2 to 
examine the degree of T-cell, B-cell, and macrophage infiltration in the tumour (using 
antibodies to the cell surface markers CD8, CD21, and CD14 respectively). Only B- 
cells were detected (again fluorescence was too unstable to photograph) and these could 
potentially be the source of the detected IL6. 
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However, since the indirect immuno-fluorescence technique does not show cell 
morphology clearly (see fig 3.12 p157) it could not be determined whether the IL6 
expression was tumour-cell associated or B-cell associated. 
4.3.4: Cytokine Production in a Bladder Tumour as Detected by Immuno-histology 
using an Alkaline Phosphatase-Con ated Secondary Antibod 9 U 
Three bladder tumours were collected, all of which were transitional cell 
carcinomas. Of these only one was suitable for immuno-histology, as the others were 
necrotic. This tumour, bladder tumour 14, gave a weak positive result for IL I a. The 
cytokine was observed in the cytoplasm of two large cells of unusual morphology 
thought to be malignant cells. Use of an antibody to the macrophage marker CD 68 
failed to detect macrophages in the tumour tissue. Therefore it is probable that IL 1a 
production in bladder tumours is tumour-cell associated. 
4.3.5 Examination of the Medical Records of the Bladder Tumour Patients. 
Examination of the clinical records of all of the patients donating bladder 
tumours yielded the following: Only one patient displayed weight loss concurrent with 
the detection of IL6 in the donated tumour (bladder tumour 2). However bladder tumour 
patients 4 and 7, both having tumours expressing IL6, had no weight loss. None of the 
bladder tumour patients had increased concentrations of calcium or globulins in their 
serum. 
206 
Bladder tumour patient 2 had an elevated white blood cell count, and bladder tumour 
patient 3 had an elevated platelet count. Bladder tumour 2 had detectable IL Ia and IL6, 
but bladder tumour 3 expressed no cytokines. These revealed no apparent correlation 
between cytokine expression in the bladder tumours and corresponding clinical 
conditions in the patients. 
4.4: Production of Inflammatory Cytokines by Lung Tumours and Non-Malignant Lung 
Tissue. 
4.4.1: Cytokine Production in Lung Tumours and Non-Malignant Lung as Determined 
by PCR. 
Eleven tumour samples were collected, 6 of which gave a positive result for ß2- 
microglobulin, and hence contained intact mRNA.. Three of the tumours were 
moderately differentiated squamous carcinomas, one was a poorly-differentiated 
adenocarcinoma, one was an invasive large cell carcinoma, and one was a bronchial 
carcinoid tumour. Intact mRNA was obtained from non-malignant tissue obtained from 
tumour-bearing patients 2,4,5, and 6. None of the tumours or non-malignant lungs 
expressed detectable IL 1a or IL 1 ß, but IL6 was detected in 5 tumour samples, and 2 
non-malignant lung samples. TNFa was detected in 1 tumour sample and in none of the 
non-malignant samples. 
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4.4.2 Cytokine Production in Lun 
Indirect Immun-fluorescence. 
Tumours and Non-Mali 9 ý ant Lun 9 as Detected b 
Frozen sections of lung tumour 4 and non-malignant lung 4 were selected for the 
immuno-fluorescence experiments. Staining was carried out for ILla and IL6 only 
because from the PCR profiling of all tumour types they were the most frequently 
observed cytokines. From the cytokine profile obtained from PCR analysis, lung tumour 4 
was expected to give a positive result for IL6 only and as expected lung tumour 4 was 
observed to fluoresce only when stained for this cytokine. However, the fluorescence was 
not of sufficient duration for photographic recording although the result was independently 
witnessed. Subsequently, indirect immuno-fluorescence was also performed on other 
sections of lung tumour 4 to examine the degree of T-cell, B-cell, and macrophage 
infiltration in the tumour (using antibodies to the cell surface markers CD8, CD21, and 
CD14 respectively). All three types of lymphocyte were detected in the tumour (again 
fluorescence was not sufficient to photograph) and any of these lymphocyte types could 
potentially be the source of the detected IL6. The non-malignant lung tissue from the 
same patient expressed IL6 only, in accordance with the result expected from PCR 
profiling. It also contained all three types of lymphocytes, any of which could be the 
source of IL6 expression. However, since the indirect immuno-fluorescence technique 
does not show cell morphology clearly (see fig 3.12 p157) the type of cells expressing it 
could not be determined. 
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4.4.3: Cytokine Production in a Lung Tumour and Non-malignant Lung Tissue as 
Detected by Immuno-histology using an Alkaline Phosphatase-Conjugated Secondary 
Antibody. 
One lung tumour was used, of unknown histological type (the record for this 
tumour patient was unavailable). Non-malignant lung from the same patient was also used 
along with a sample of non-malignant lung from a non-cancer patient. The lung tumour 
gave positive staining for IL6 only, which was observed in a large cell suspected to be 
malignant. Staining of the tumour with macrophages failed to detect their presence. The 
non-malignant lung from this patient also stained positively for IL6 only, this time the 
result was observed in large surface cells. Staining for macrophages showed these to be 
present in the non-malignant tissue, but they were not of the same cell morphology as the 
large surface cells producing IL6. The non-malignant lung from a non-cancer patient 
showed no expression of IL Ia or IL6 and no macrophages present. Partial corroboration 
of the expression of IL6 by the lung tumour cells is provided by Mizuno et al (1994) who 
reported the production of IL6 in-vitro by some lung tumour cell lines. Absence of IL Ia 
in the lung tumours in all the studies is confirmed by Arias-Dias (1994). 
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4.4.4 Examination of the Medical Records of the Lung Tumour Patients. 
Examination of the available clinical records of all the patients donating lung 
tumours yielded the following: None of the lung tumour patients showed any correlation 
between type or grade of tumour and IL6 expression. Weight loss was observed in lung 
tumour patient 2. However, this did not correlate with cytokine expression as lung tumour 
6 expressed IL6 but lung tumour 2 did not. Lung tumour patient 6 displayed an elevated 
globulin count, white blood cell count and neutrophil count. Lung tumour patients 3 and 4 
had elevated white blood cell counts and neutrophil counts. All 3 of the corresponding 
tumours displayed detectable IL6. This might indicate a tenuous link between IL6 
expression in these patients and systemic inflammation. However, since lung tumour 
patient 5 had a tumour displaying II. 6 but no signs of inflammation, and the correlations 
between elevated globulin concentrations, white blood cell counts, and neutrophil counts 
and IL6 expression are not as good as those between elevated acute phase protein 
concentrations and IL6 expression, no clear conclusions can be made. 
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4.5: Production of Inflammatory Cytokines by Ovarian Tumours. 
Only two ovarian tumours were collected, as few tumours of this type were 
available. Two non-malignant cystic ovaries from a non-cancer patient were also 
collected. 
4.5.1: Cytokine Production in Ovarian Tumours and Non-Malignant Ovarian tissue as 
Determined by PCR. 
Malignant ovarian tumour 1 expressed IL Ia and IL Iß only, and malignant 
ovarian tumour 2 expressed TNFa only. The 2 non-malignant ovaries from different 
patients both displayed IL la only. The results might imply an association between IL1ß 
production and ovarian tumours, but the number of tumours examined was too small to 
say this with any degree of certainty. The fact that no IL6 was detected in either tumour is 
contradicted by Plante et al (1994) who found that there was IL6 in the serum of many 
ovarian cancer patients. These concentrations correlated with tumour size and ascites 
volume, but not with survival time or grade. further studies are required with a larger 
number of malignant ovarian tumours in order to establish the possible association 
between ILl Band these tumours. 
There was insufficient ovarian tumour or non-malignant ovarian material for use in 
the immuno-fluorescence experiments, and no tumours or non-malignant material were 
available during the course of the immuno-histology experiments carried out using the 
alkaline phosphatase method. 
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4.5.2Examination of the Medical Records of the Ovarian Tumour Patients. 
Examination of the available clinical records of all the patients donating material 
yielded the following: Neither of the two ovarian tumour patients displayed weight loss 
and neither had an elevated concentration in serum of globulin, but malignant ovary 
patient 1 had elevated white blood cell and platelet counts. This may possibly have been 
due to systemic action of IL1, but this cannot be concluded for certain from the available 
data. 
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4.6: Possible Effects of IL6 on Tumour Cells. 
Since IL6 was the most commonly observed cytokine in most of the tumour types 
studied, experiments were carried out on the T-24 bladder and MCF-7 cell lines to 
determine if IL6 had any effect on cell growth A previous study by Miki et al (1989) 
showed that IL6 was an autocrine growth factor for a renal carcinoma cell line. It was 
therefore possible that IL6 might be an autocrine growth factor for either cell line as 
both were observed to produce it. Two experiments were performed 
. The first examined the effects of crude 
IL6 on the growth of the MCF-7 cell 
line over a 96h period. Inhibition of growth was observed after 48h at a dose of 36 
U/ml. 
The second experiment examined the effect of recombinant IL6 on growth over a 
72h period. The effects of IL6 were also measured on the T-24 cell line and the B-9 
hybridoma cell line (which is dependant on IL6 for growth) which was used as a positive 
control. This experiment showed that growth of the MCF-7 cell line was inhibited by 
concentrations of recombinant IL6 greater than 30 pg/ml after 48h, but that the growth 
of the T-24 cell line was unaffected by any dose of IL6 used. As expected, IL6 
promoted the growth of the B-9 hybridoma in a dose-dependant manner. 
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The results of the experiments may point to IL6 being an autocrine growth 
inhibitor for MCF-7 cells. The findings agree with those of Chen et al (1988), who have 
reported that IL6 causes growth inhibition in this cell line at doses of 10 - 250 U/ml. 
Danforth et al (1993) also report growth inhibition of MCF-7 cells by IL6, but at a 
higher concentration of 1000 U/ml. Significantly, they also observed growth 
inhibition by IL! a at the same concentration. This growth inhibition was even greater 
than that seen with IL6. However, most noticeable of all was a synergistic effect of 
M cc a with IL6. This may be very significant, as the MCF-7 cell line was seen to 
produce both cytokines constitutively in the experiments described in this thesis. 
The mechanism whereby IL6 might be an autocrine growth inhibitor for MCF-7 
cells is unclear. The fact that it was only detected in cell cultures at full confluence may 
have some significance. These cultures were incapable of further growth due to no 
more free surface area being available for expansion. It might be logical to assume that 
this set of circumstances could result in the production of a growth inhibitor by the cells. 
However, it is also worth noting that due to the work of Danforth et al, the growth 
inhibition is probably a result of added IL6 working in synergy with constitutively 
produced IL 1 a. In the experiments described here, this effect of IL 1a was unknown as 
the work predated that of Danforth et al. Therefore, no effort was made to block the 
synthesis of IL Ia by the cells, or add it with IL6 to see if this augmented the growth 
inhibition. It is also possible that neither IL 1a or IL6 is the primary mediator of the 
growth inhibition. 
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It is possible that they stimulate the production of a secondary factor, and this may 
explain growth inhibition occurring after 48h. A likely candidate for this substance is 
Transforming Growth Factor Beta (TGFB). Knabbe et al (1987), and Zugmier and 
Lippman (1990), have both demonstrated that TGFB is a potent growth inhibitor for the 
MCF-7 cell line. Danforth et al demonstrated that IL 1a (which had more of a growth 
inhibiting effect than IL6) increased the production of TGFB, lending some credence to 
the idea of the involvement of TGFB in the growth inhibition. 
The true nature of growth inhibition in the MCF-7 cell line would seem therefore 
to be complex, but does seem to involve IL6. It would be worthwhile to perform future 
experiments, perhaps using antibodies to IL! a, IL6, and TGFB to see how this might 
affect the growth inhibition. This study could also be expanded to examine the precise 
mechanism of IL Ia and IL6 expression in the MCF-7 cells. 
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4.7: Final Conclusions and Viability of the Inflammatory Cytokines as Tumour 
Markers. 
The research presented in this thesis showed that all of the inflammatory 
cytokines could be observed in primary samples of tumours by the detection methods 
employed. However, because of the small number of tumours examined, further studies 
need to be undertaken to confirm the findings and investigate the usefulness of the 
inflammatory cytokines as tumour markers. These would incorporate larger numbers of 
tumours, and where possible, the use of non-malignant control tissue from both tumour- 
bearing patients and normal individuals. An examination of concentrations of cytokines 
in serum from tumour patients and normal individuals would also be necessary. 
4.7.1 Recommendations for Methodologies to Detect Cvtokines in Samples of Primary 
Tumours. 
The studies presented in this thesis have demonstrated that reverse-transcription- 
PCR (RT-PCR) can detect cytokines in some bulk tumour samples. However, there are 
problems with the technique as it stands. In nearly all cases only 50% of tumours 
collected had intact mRNA as assessed by the presence of ß2 microglobulin. This is 
probably due to time delays in obtaining tumour samples These may be unavoidable due 
to the need for samples to be examined by a pathologist prior to being snap frozen. In 
the case of bladder tumours the nature of tumour removal leads to destruction of the 
integrity of the tumour. It was also thought that the RT-PCR method was not 
sufficiently sensitive enough to detect low levels of cytokines in some of the material. 
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IL 1a could not be detected in breast tumours by this method and could be detected by 
immuno-histology. Clearly the sensitivity of the technique would need to be increased. 
One approach to this would be to employ a PCR technique using nested primers. 
In this technique, PCR is performed as normal, but the products of the amplification are 
then subjected to a further round of PCR using internal primers to sequences in the product 
DNA. This results in much higher amplification and therefore is a good method for 
detecting very small amounts of mRNA in bulk tissue samples. One example of a 
successful application of this technique has been the use of a nested-primer PCR protocol 
to detect very small amounts of endothelin-2 and endothelia-3 (both low molecular mass 
vasoactive polypeptides) in human endometrium (O'Reilly et al 1992). 
Both the indirect immuno-fluorescence and alkaline-phosphatase based immuno- 
histology techniques successfully detected cytokine polypeptide in all of the tumour 
samples in which they were used. Comparison of the results of the two methods would 
suggest that the second technique is superior. Not only is it sensitive but it also gives a 
clear picture of cell morphology. This is not the case with indirect inununo-fluorescence. 
However immuno-histology techniques have limitations. While they can detect some 
cytokine polypeptide in cells, most is observed in the surrounding stroma (this was 
particularity the case with IL6 in the breast tumours) so direct cell-association with 
particular cytokines often cannot be clearly demonstrated. While better verification of 
cell-associated cytokine protein can be obtained using confocal microscopy it is only in- 
situ hybridisation that achieves this beyond doubt. 
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First developed by Gall and Pardue in 1969, this method can detect particular sequences 
of mRNA in cells. If it were used to detect cytokine mRNA in tumour sections then any 
cell association would be clearly demonstrated. 
4.7.2: Assessment of the Usefulness of Inflammatory Cytokines as Tumour Markers. 
The findings presented in this thesis, when considered in association with other 
published work would suggest that all of the inflammatory cytokines could potentially 
be used as tumour markers, with IL Ia and IL6 being the best candidates. This is based 
on their frequency of occurrence in most tumour types. However, their usefulness as 
tumour markers would depend on how well they fulfil the criteria of Beastall et al, out- 
lined on p23. Assessment of specificity or sensitivity as outlined by Beastall et al cannot 
be determined. Lack of suitable control material for most of the tumour types examined 
meant that numbers of false positive or false negative results could not be determined 
and these are necessary to work out true specificity or sensitivity of a tumour marker. 
False positive or negative results can only be determined by using healthy individuals as 
controls, and this cannot be done unless the assessment of the tumour marker is based on 
its measurement in serum or bodily fluids. Where the terms are mentioned in the 
following sections, they are used in a different sense ie: specificity of detection, 
meaning that the cytokine was detected in the tumour tissue but not in non-malignant 
material of the same type (often from the same patient), and sensitivity of detection, 
meaning how easily the cytokine was detected in the tumour sample. 
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4.7.2.1.: Usefulness of ILIa as a Tumour Marker. 
In the experiments reported in the thesis IL 1a was observed in breast tumours, 
bladder tumours and ovarian tumours. The sensitivity of detection of it was good in all 
three tumour types, but the degree of specificity of detection could not be adequately 
assessed due to control tissue only being available for the ovarian tumours. This 
demonstrated that both malignant and non-malignant ovarian tissue could produce 
IL 1 a. There was no correlation between IL 1a expression in the tumours and tumour 
grade, stage, or mass. However, these features, which are necessary to define a 
prognostic marker, would be best observed from measurements of IL Ia concentration in 
bodily fluids (especially serum). This was beyond the scope of this thesis but could be 
the subject of further study if adequate methods for measurement of IL I in bodily fluids 
became available. Eastgate et al (1990) demonstrated that IL I is bound to a binding 
protein in plasma. While Capper et al (1990) showed that IL Iß can be dissociated from 
its binding protein by acid treatment it is not possible to do this with IL I a. The bound 
form of IL 1a in serum cannot accurately be measured by sandwich ELISA (enzyme- 
linked immuno-sorbant assay). Bio-assays for IL Ia will also not give an accurate result 
due to the presence of an IL I antagonist in serum and other bodily fluids (Liao et al 
1984; Mazzei et al , 
1990). It therefore seems unlikely that IL 1a would make a useful 
biochemical marker in cancer. Indeed the difficulty in its accurate measurement may 
explain why, for example, Moradai et al (1993) failed to detect IL 1a in the serum of 
ovarian cancer patients. 
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4.7.2.2.: Usefulness of IL6 as a Tumour Marker. 
IL6 occurred with reasonable frequency in breast, bladder, and lung tumours (10 
/13,7/13, and 6/7 samples respectively). Sensitivity of detection (judging from the 
immuno-histology results ) was good. Specificity of detection was not good, as IL6 
could be detected in non-malignant lung (3/5 samples) and IL6 expression has also been 
reported in non-malignant breast tissue (Basolo et al, 1993). There were no apparent 
correlations between tumour IL6 expression and prognostic factors. However to 
ascertain this properly it would be necessary to measure IL6 concentrations in bodily 
fluids of large numbers of cancer patients and compare them with similar measurements 
in healthy individuals. Unlike IL 1 a, IL6 can be measured in serum. It does bind to a 
carrier protein but this does not affect its measurement by ELISA and its bound form is 
bio-active. It has been successfully measured in the urine of bladder cancer patients 
(Seguchi et al, 1992) and found to be specific (39 cancer patients had raised 
concentrations of IL6 in their urine but there was no significant expression in 15 healthy 
individuals) and to correlate with progression of tumour stage. Ferdighini et al (1994) 
successfully showed a correlation between raised concentrations of IL6 in the serum of 
cervical cancer patients and tumour stage, and Plante et al (1994) demonstrated that 
concentrations of IL6 in serum from ovarian cancer patients correlates with tumour size 
and ascitic volume. Gogusev et al (1993) report good specificity for IL6 in renal 
carcinomas but no clinical correlations. 
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It therefore seems possible that IL6 is a good candidate for a new tumour marker and it 
would be rewarding to measure concentrations in serum of IL6 in breast, bladder and lung 
tumour-bearing patients to establish whether there is concentration-dependent specificity 
and correlation between IL6 concentrations in serum and prognostic features. 
4.7.2.3.: Usefulness of TNFa as a Tumour Marker. 
In the studies performed in the thesis, TNFa was seen to occur with fairly low 
frequency but was seen in a few samples from all the tumour groups (2/9 breast tumours, 
1/13 bladder tumours, 1 /6 lung tumours). The number of tumours of any type was too 
small to establish whether correlations could be made between TNFa expression and 
prognostic factors such as tumour stage or grade. 
However, the method used to detect TNFa was RT-PCR, which showed poor 
sensitivity. In the breast tumours, TNFa was detected in only 2 out of 9 tumours. Miles 
et al (1994), using immuno-histology, found TNFa expression in stromal cells in 43 out of 
49 breast tumours examined, and this expression correlated with tumour grade. Bebok et 
al (1994) also detected TNFa by immuno-histology in malignant breast tumours and 
found that its expression correlated with clinical staging, tumour grade, lymph node 
metastasis, tumour recurrence and survival time of the patient. Immuno-histological 
methods have also successfully detected TNFa in ovarian tumours. 
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Takeyama et al (1991) found TNFa expression in 16 out of 20 ovarian tumours and in 4 
out of 5 ascitic fluid specimens. In the RT-PCR experiments, 1 out of 2 malignant 
ovarian tumours expressed TNFa so this tenuously agrees with their results. It seems 
likely therefore that further work on TNFa as a potential histological marker for some 
types of tumour is warranted. Furthermore Knapp et al (1991) have demostrated 
increased concentrations of TNFa in the serum of cachectic breast tumour patients with 
stage IV tumours using an ELISA.. This work should be followed up. 
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4.8: Outlines for Future Work. 
Of all the results presented in the thesis, those obtained from the breast tumours 
offer the best area for future investigation. At present published confirmatory evidence 
that these tumours produce IL6 and IL! a is not available. It would therefore be 
desirable to initiate a new study to examine IL! a and IL6 expression in breast tumours 
in more detail. The study could be set up as follows: 
1) A new collection of breast tumours would be gathered, the number of samples being 
large enough (preferably over 30) to give enough material for proper statistical 
correlations. Non-malignant breast tissue from the same patients would be collected, if 
possible, to determine the specificity of any cytokine expression and additional controls 
would be introduced through the input of normal breast material, for example from 
breast reduction mammoplasties. 
2) PCR and immuno-histology using the alkaline phosphatase technique would be 
employed in tandem where tumour samples were large enough (tissue would have to be 
collected both snap-frozen and fixed in formalin) and thus reduce the possibility of 
conflicting results such as those already observed in the thesis. 
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3) Blood samples from all patients in the study would be collected, allowing 
measurement of serum cytokine concentrations. Cytokines expressed by tumours may 
not necessarily enter the bloodstream of the patients and this could only be determined 
by comparing cytokine concentrations in the serum samples from the tumour group with 
those in the control group. Limitations on the ability of methods to measure IL 1a 
accurately in serum would have to be taken into account. 
4) Both erythrocyte sedimentation rates, and concentrations in serum of acute phase 
proteins such as CRP correlate well with increased concentrations in serum of IL6 
(Bedell et al, 1985) Consequently, the intention would be to introduce such assays into 
the work. 
5) The samples used in the second immuno-histology experiments could be re- 
examined (they are held in storage) using in-situ hybridisation to probe for IL Ia mRNA 
as successful detection of this would provide a means of resolving the conflicting results 
already reported between the original PCR and immuno-histology study. If the 
technique proved successful on these samples it could also be used on the material 
collected in the new study, allowing the cellular source of detected cytokines to be 
verified. 
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The information gained from this extended study when added to the data already 
reported in this thesis would establish whether IL6 is a useful biochemical breast tumour 
marker and perhaps establish IL 1a as a histological marker. This plan of investigation 
could also be adopted to examine the production of cytokines by other tumour types not 
covered by the thesis. The scope for further research is considerable and many questions 
remain to be answered. 
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